NZ736967B2 - Use of il-15 to increase thymic output and to treat lymphopenia - Google Patents
Use of il-15 to increase thymic output and to treat lymphopenia Download PDFInfo
- Publication number
- NZ736967B2 NZ736967B2 NZ736967A NZ73696710A NZ736967B2 NZ 736967 B2 NZ736967 B2 NZ 736967B2 NZ 736967 A NZ736967 A NZ 736967A NZ 73696710 A NZ73696710 A NZ 73696710A NZ 736967 B2 NZ736967 B2 NZ 736967B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- seq
- nucleic acid
- complex
- lymphocytes
- Prior art date
Links
- 206010025327 Lymphopenia Diseases 0.000 title claims abstract description 45
- 231100001023 lymphopenia Toxicity 0.000 title claims abstract description 42
- 230000002992 thymic Effects 0.000 title description 17
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 448
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 448
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 17
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 13
- 102000037240 fusion proteins Human genes 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 229920000023 polynucleotide Polymers 0.000 claims description 61
- 239000002157 polynucleotide Substances 0.000 claims description 61
- 150000007523 nucleic acids Chemical class 0.000 claims description 56
- 241000282414 Homo sapiens Species 0.000 claims description 39
- 229920001184 polypeptide Polymers 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 230000004927 fusion Effects 0.000 claims description 25
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 11
- 102000018358 Immunoglobulins Human genes 0.000 claims description 9
- 108060003951 Immunoglobulins Proteins 0.000 claims description 9
- 102000003978 Tissue plasminogen activator Human genes 0.000 claims description 7
- 108090000373 Tissue plasminogen activator Proteins 0.000 claims description 7
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 7
- 108010051696 Growth Hormone Proteins 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108091006004 Fc-tagged proteins Proteins 0.000 abstract description 9
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 abstract description 8
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 abstract description 8
- 101700078894 GNAL Proteins 0.000 abstract 1
- 108010053727 Interleukin-15 Receptor alpha Subunit Proteins 0.000 description 122
- 210000004698 Lymphocytes Anatomy 0.000 description 112
- 210000004027 cells Anatomy 0.000 description 100
- 210000001744 T-Lymphocytes Anatomy 0.000 description 91
- 210000001519 tissues Anatomy 0.000 description 80
- 230000002093 peripheral Effects 0.000 description 69
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 63
- 210000001541 Thymus Gland Anatomy 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 40
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 37
- 210000000952 Spleen Anatomy 0.000 description 37
- 210000004072 Lung Anatomy 0.000 description 36
- 230000035492 administration Effects 0.000 description 36
- 239000007924 injection Substances 0.000 description 31
- 102100013077 CD4 Human genes 0.000 description 30
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 26
- 210000001185 Bone Marrow Anatomy 0.000 description 21
- 238000002347 injection Methods 0.000 description 21
- 230000005012 migration Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 230000035800 maturation Effects 0.000 description 19
- 238000011084 recovery Methods 0.000 description 19
- 210000003719 B-Lymphocytes Anatomy 0.000 description 18
- 230000001737 promoting Effects 0.000 description 18
- 230000001965 increased Effects 0.000 description 17
- 239000000833 heterodimer Substances 0.000 description 16
- 229960004397 Cyclophosphamide Drugs 0.000 description 15
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000000975 bioactive Effects 0.000 description 15
- 108010002350 Interleukin-2 Proteins 0.000 description 14
- 102000000588 Interleukin-2 Human genes 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 210000004369 Blood Anatomy 0.000 description 13
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 13
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 13
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 238000007910 systemic administration Methods 0.000 description 12
- 229920001405 Coding region Polymers 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 210000000207 Lymphocyte Subsets Anatomy 0.000 description 10
- 230000036823 Plasma Levels Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007172 antigens Proteins 0.000 description 9
- 102000038129 antigens Human genes 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 102100006400 CSF2 Human genes 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 210000000056 organs Anatomy 0.000 description 8
- 108010031719 prolyl-serine Proteins 0.000 description 8
- 102000015696 Interleukins Human genes 0.000 description 7
- 108010063738 Interleukins Proteins 0.000 description 7
- 210000004185 Liver Anatomy 0.000 description 7
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 108010048818 seryl-histidine Proteins 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 241000282465 Canis Species 0.000 description 6
- 241000282324 Felis Species 0.000 description 6
- 210000004837 Gut-associated lymphoid tissue Anatomy 0.000 description 6
- 102100004550 IL15RA Human genes 0.000 description 6
- 101710035264 IL15RA Proteins 0.000 description 6
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 6
- 241000282553 Macaca Species 0.000 description 6
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 6
- LDEBVRIURYMKQS-UHFFFAOYSA-N Serinyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CO LDEBVRIURYMKQS-UHFFFAOYSA-N 0.000 description 6
- 210000002966 Serum Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000002147 killing Effects 0.000 description 6
- 230000003836 peripheral circulation Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 108010026333 seryl-proline Proteins 0.000 description 6
- 230000002459 sustained Effects 0.000 description 6
- 206010059512 Apoptosis Diseases 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 5
- DRCKHKZYDLJYFQ-UHFFFAOYSA-N Isoleucyl-Threonine Chemical compound CCC(C)C(N)C(=O)NC(C(C)O)C(O)=O DRCKHKZYDLJYFQ-UHFFFAOYSA-N 0.000 description 5
- 210000001165 Lymph Nodes Anatomy 0.000 description 5
- 108020004999 Messenger RNA Proteins 0.000 description 5
- 108090001123 antibodies Proteins 0.000 description 5
- 102000004965 antibodies Human genes 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 108010057821 leucylproline Proteins 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 4
- BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 4
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 101700082799 IL2RA Proteins 0.000 description 4
- 102100002950 ISG20 Human genes 0.000 description 4
- 101700015336 ISG20 Proteins 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 4
- 102400000046 Soluble interleukin-15 receptor subunit alpha Human genes 0.000 description 4
- 101800000582 Soluble interleukin-15 receptor subunit alpha Proteins 0.000 description 4
- VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 4
- BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 description 4
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 4
- ZSXJENBJGRHKIG-UHFFFAOYSA-N Tyrosyl-Serine Chemical compound OCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UHFFFAOYSA-N 0.000 description 4
- GVRKWABULJAONN-UHFFFAOYSA-N Valyl-Threonine Chemical compound CC(C)C(N)C(=O)NC(C(C)O)C(O)=O GVRKWABULJAONN-UHFFFAOYSA-N 0.000 description 4
- 108010047495 alanylglycine Proteins 0.000 description 4
- 108010087924 alanylproline Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 231100000486 side effect Toxicity 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- OPINTGHFESTVAX-UHFFFAOYSA-N γ-glutamyl-Arginine Chemical compound NC(=O)CCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N OPINTGHFESTVAX-UHFFFAOYSA-N 0.000 description 4
- 101700078950 CD44 Proteins 0.000 description 3
- 102100003735 CD44 Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 102100008842 GH1 Human genes 0.000 description 3
- HHSJMSCOLJVTCX-UHFFFAOYSA-N Glutaminyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CCC(N)=O HHSJMSCOLJVTCX-UHFFFAOYSA-N 0.000 description 3
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 3
- 208000005721 HIV Infections Diseases 0.000 description 3
- 210000002216 Heart Anatomy 0.000 description 3
- 206010020243 Hodgkin's disease Diseases 0.000 description 3
- 108090001095 Immunoglobulin G Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 210000004324 Lymphatic System Anatomy 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- 210000004693 NK cell Anatomy 0.000 description 3
- 210000002741 Palatine Tonsil Anatomy 0.000 description 3
- 210000001986 Peyer's Patches Anatomy 0.000 description 3
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102100008254 SELL Human genes 0.000 description 3
- 101710038663 SELL Proteins 0.000 description 3
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 3
- YZMPDHTZJJCGEI-BQBZGAKWSA-N Ser-His Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 YZMPDHTZJJCGEI-BQBZGAKWSA-N 0.000 description 3
- 210000003462 Veins Anatomy 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 230000001605 fetal Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 3
- 230000019697 interleukin-15 production Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 210000003519 mature B lymphocyte Anatomy 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 210000003071 memory T lymphocyte Anatomy 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 108010077112 prolyl-proline Proteins 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- JSZMKEYEVLDPDO-ACZMJKKPSA-N (2R)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-sulfanylpropanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O JSZMKEYEVLDPDO-ACZMJKKPSA-N 0.000 description 2
- VNYDHJARLHNEGA-RYUDHWBXSA-N (2S)-1-[(2S)-2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylate Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 2
- ZJZNLRVCZWUONM-JXUBOQSCSA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]propanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 2
- KIUYPHAMDKDICO-WHFBIAKZSA-N (3S)-3-[[(2S)-2-aminopropanoyl]amino]-4-(carboxymethylamino)-4-oxobutanoic acid Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 2
- XUUXCWCKKCZEAW-YFKPBYRVSA-N 2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 2
- HKTRDWYCAUTRRL-UHFFFAOYSA-N 4-amino-5-[[1-carboxy-2-(1H-imidazol-5-yl)ethyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CN=CN1 HKTRDWYCAUTRRL-UHFFFAOYSA-N 0.000 description 2
- XAEWTDMGFGHWFK-IMJSIDKUSA-N Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O XAEWTDMGFGHWFK-IMJSIDKUSA-N 0.000 description 2
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 2
- ZSOICJZJSRWNHX-ACZMJKKPSA-N Ala-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)[C@H](C)[NH3+] ZSOICJZJSRWNHX-ACZMJKKPSA-N 0.000 description 2
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 2
- SITWEMZOJNKJCH-UHFFFAOYSA-N Alanyl-Arginine Chemical compound CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 2
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 2
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 2
- XTWSWDJMIKUJDQ-RYUDHWBXSA-N Arg-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XTWSWDJMIKUJDQ-RYUDHWBXSA-N 0.000 description 2
- XNSKSTRGQIPTSE-UHFFFAOYSA-N Arginyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CCCNC(N)=N XNSKSTRGQIPTSE-UHFFFAOYSA-N 0.000 description 2
- VBKIFHUVGLOJKT-UHFFFAOYSA-N Asparaginyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC(N)=O VBKIFHUVGLOJKT-UHFFFAOYSA-N 0.000 description 2
- NTQDELBZOMWXRS-UHFFFAOYSA-N Aspartyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC(O)=O NTQDELBZOMWXRS-UHFFFAOYSA-N 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 206010003885 Azotaemia Diseases 0.000 description 2
- BVRPESWOSNFUCJ-LKTVYLICSA-N BNC210 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 BVRPESWOSNFUCJ-LKTVYLICSA-N 0.000 description 2
- 241000030939 Bubalus bubalis Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- ZSRSLWKGWFFVCM-WDSKDSINSA-N Cys-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O ZSRSLWKGWFFVCM-WDSKDSINSA-N 0.000 description 2
- VBIIZCXWOZDIHS-UHFFFAOYSA-N Cysteinyl-Isoleucine Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CS VBIIZCXWOZDIHS-UHFFFAOYSA-N 0.000 description 2
- OELDIVRKHTYFNG-UHFFFAOYSA-N Cysteinyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)CS OELDIVRKHTYFNG-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- JEFZIKRIDLHOIF-BYPYZUCNSA-N Gln-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(O)=O JEFZIKRIDLHOIF-BYPYZUCNSA-N 0.000 description 2
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 2
- ARPVSMCNIDAQBO-UHFFFAOYSA-N Glutaminyl-Leucine Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CCC(N)=O ARPVSMCNIDAQBO-UHFFFAOYSA-N 0.000 description 2
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 2
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 210000001308 Heart Ventricles Anatomy 0.000 description 2
- VHOLZZKNEBBHTH-YUMQZZPRSA-N His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 VHOLZZKNEBBHTH-YUMQZZPRSA-N 0.000 description 2
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 2
- KRBMQYPTDYSENE-BQBZGAKWSA-N His-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 KRBMQYPTDYSENE-BQBZGAKWSA-N 0.000 description 2
- NIKBMHGRNAPJFW-UHFFFAOYSA-N Histidinyl-Arginine Chemical compound NC(=N)NCCCC(C(O)=O)NC(=O)C(N)CC1=CN=CN1 NIKBMHGRNAPJFW-UHFFFAOYSA-N 0.000 description 2
- 101000074809 IL15 Proteins 0.000 description 2
- 102100001475 ITGB2 Human genes 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108010043156 Immunoglobulin D Proteins 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 102000016551 L-Selectin Human genes 0.000 description 2
- VYZAGTDAHUIRQA-WHFBIAKZSA-N L-alanyl-L-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-WHFBIAKZSA-N 0.000 description 2
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 description 2
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 2
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 2
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 2
- UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 2
- JPNRPAJITHRXRH-UHFFFAOYSA-N Lysyl-Asparagine Chemical compound NCCCCC(N)C(=O)NC(C(O)=O)CC(N)=O JPNRPAJITHRXRH-UHFFFAOYSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- ADHNYKZHPOEULM-BQBZGAKWSA-N Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O ADHNYKZHPOEULM-BQBZGAKWSA-N 0.000 description 2
- DZMGFGQBRYWJOR-YUMQZZPRSA-N Met-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O DZMGFGQBRYWJOR-YUMQZZPRSA-N 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 102100005499 PTPRC Human genes 0.000 description 2
- 101700059076 PTPRC Proteins 0.000 description 2
- 229920002224 Peptide nucleic acid Polymers 0.000 description 2
- ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- SHAQGFGGJSLLHE-BQBZGAKWSA-N Pro-Gln Chemical compound NC(=O)CC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 SHAQGFGGJSLLHE-BQBZGAKWSA-N 0.000 description 2
- AFWBWPCXSWUCLB-WDSKDSINSA-N Pro-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 AFWBWPCXSWUCLB-WDSKDSINSA-N 0.000 description 2
- 229920001914 Ribonucleotide Polymers 0.000 description 2
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 2
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 description 2
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 2
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 2
- SBMNPABNWKXNBJ-UHFFFAOYSA-N Serinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CO SBMNPABNWKXNBJ-UHFFFAOYSA-N 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 2
- 210000002978 Thoracic Duct Anatomy 0.000 description 2
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 2
- UQTNIFUCMBFWEJ-UHFFFAOYSA-N Threoninyl-Asparagine Chemical compound CC(O)C(N)C(=O)NC(C(O)=O)CC(N)=O UQTNIFUCMBFWEJ-UHFFFAOYSA-N 0.000 description 2
- PWIQCLSQVQBOQV-AAEUAGOBSA-N Trp-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 PWIQCLSQVQBOQV-AAEUAGOBSA-N 0.000 description 2
- YBRHKUNWEYBZGT-UHFFFAOYSA-N Tryptophyl-Threonine Chemical compound C1=CC=C2C(CC(N)C(=O)NC(C(O)C)C(O)=O)=CNC2=C1 YBRHKUNWEYBZGT-UHFFFAOYSA-N 0.000 description 2
- 208000009852 Uremia Diseases 0.000 description 2
- BNQVUHQWZGTIBX-IUCAKERBSA-N Val-His Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CN=CN1 BNQVUHQWZGTIBX-IUCAKERBSA-N 0.000 description 2
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 2
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- 230000001640 apoptogenic Effects 0.000 description 2
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- STKYPAFSDFAEPH-LURJTMIESA-N gly-val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 108010018006 histidylserine Proteins 0.000 description 2
- 102000032399 human IL15 protein Human genes 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 108010027338 isoleucylcysteine Proteins 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 108010000761 leucylarginine Proteins 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 101700006434 pept-1 Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- QLROSWPKSBORFJ-BQBZGAKWSA-N pro glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 QLROSWPKSBORFJ-BQBZGAKWSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 2
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting Effects 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 230000003248 secreting Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- BQSLGJHIAGOZCD-CIUDSAMLSA-N (2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]-3-hydroxypropanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229960004176 Aclarubicin Drugs 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N Acridine orange Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- JQDFGZKKXBEANU-UHFFFAOYSA-N Alanyl-Cysteine Chemical compound CC(N)C(=O)NC(CS)C(O)=O JQDFGZKKXBEANU-UHFFFAOYSA-N 0.000 description 1
- 108010090726 Alefacept Proteins 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- TWXZVVXRRRRSLT-UHFFFAOYSA-N Asparaginyl-Cysteine Chemical compound NC(=O)CC(N)C(=O)NC(CS)C(O)=O TWXZVVXRRRRSLT-UHFFFAOYSA-N 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 102100015655 BCL2L1 Human genes 0.000 description 1
- 101710032374 BCL2L1 Proteins 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-M COP([O-])=O Chemical class COP([O-])=O QCMYYKRYFNMIEC-UHFFFAOYSA-M 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N Carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 102000020504 Collagenase family Human genes 0.000 description 1
- 108060005980 Collagenase family Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N Deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 101700079760 EFCB Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 101710005090 ERVFC1-1 Proteins 0.000 description 1
- 101710013371 ERVS71-1 Proteins 0.000 description 1
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 description 1
- 229940029575 Guanosine Drugs 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 102100019336 ITGA2 Human genes 0.000 description 1
- 101710006710 ITGA2 Proteins 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 description 1
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 1
- OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KAKJTZWHIUWTTD-VQVTYTSYSA-N Met-Thr Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)O)C([O-])=O KAKJTZWHIUWTTD-VQVTYTSYSA-N 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N Neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 230000037289 Plasma half life Effects 0.000 description 1
- 230000037240 Plasma half-life Effects 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100019667 STAT3 Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- RZEQTVHJZCIUBT-UHFFFAOYSA-N Serinyl-Arginine Chemical compound OCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-UHFFFAOYSA-N 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- KAFKKRJQHOECGW-JCOFBHIZSA-N Thr-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(O)=O)=CNC2=C1 KAFKKRJQHOECGW-JCOFBHIZSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- CKHWEVXPLJBEOZ-UHFFFAOYSA-N Threoninyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)C(C)O CKHWEVXPLJBEOZ-UHFFFAOYSA-N 0.000 description 1
- UPJONISHZRADBH-XPUUQOCRSA-N Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UPJONISHZRADBH-XPUUQOCRSA-N 0.000 description 1
- STTYIMSDIYISRG-WDSKDSINSA-N Val-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(O)=O STTYIMSDIYISRG-WDSKDSINSA-N 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 238000011030 bottleneck Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N dCyd Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-O hydron;2H-tetrazole Chemical compound C1=NN=[NH+]N1 KJUGUADJHNHALS-UHFFFAOYSA-O 0.000 description 1
- 210000002861 immature T-cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 230000000329 lymphopenic Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001939 mature NK cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 210000001806 memory B lymphocyte Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 101700016463 pls Proteins 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000979 retarding Effects 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Abstract
Disclosed is the use of (a) an IL-15 and a soluble IL-15R? (IL-15/IL-15sR?) complex and (b) an IL-15 and IL-15R?Fc fusion protein (IL-15/IL-15R?Fc) complex in the manufacture of a medicament for treating lymphopenia. IL-15RaFc fusion protein comprises a truncated IL-15Ra. The IL-15 may comprise a signal peptide from a heterologous protein. The patient may be receiving a chemotherapeutic agent. gnal peptide from a heterologous protein. The patient may be receiving a chemotherapeutic agent.
Description
USE OF IL-15 TO INCREASE THYMIC OUTPUT AND TO TREAT
LYMPHOPENIA
This is a divisional application of New Zealand patent application 714757, which
itself is divided out of NZ 625008, which itself is divided out of NZ 597814 dated 13 August
2010.
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims benefit of U.S. provisional application no. 61/234,152, filed
August 14, 2009; and U.S. provisional application no. 61/234,155, filed August 14, 2009.
Each application is herein incorporated by reference.
FIELD OF THE INVENTION
The present disclosure is directed to compositions and methods for promoting the
maturation and export of T cells from the thymus, e.g., to peripheral lymphoid and non-
lymphoid tissues by contacting the thymus tissue, in vitro or in vivo, with interleukin (IL)-15.
The disclosure additionally describes methods for preventing, alleviating, reducing,
and/or inhibiting lymphopenia or depletion of lymphocytes in peripheral tissues in a patient
in need thereof by administering IL-15 to the patient.
BACKGROUND OF THE INVENTION
Two common gamma-chain cytokines, IL-2 and IL-7 are currently approved or
considered for both AIDS and cancer immunotherapy. See, Sportes, et al., (2008) J Exp Med
205:1701-1714; Levy, Y. (2009) J Clin Invest. 119(4):997-100785; and Rosenberg, et al.,
(2006) J Immunother 29:313-319. No clinical experience exists with the gamma-chain
cytokine IL-15. See, Cheever, (2008) Immunological Reviews 222:357-368.
IL-15 is a non-redundant cytokine important for the development, survival, and
proliferation of natural killer (NK) and CD8+ T-cells. It shares with IL-2 the same IL-2 beta
gamma receptor and has many similar effects on lymphocytes, but unlike IL-2 is not
produced by lymphocytes but by a plethora of other cells including, importantly, antigen
presenting cells and macrophages, and stroma cells in several tissues. The biological effects
of IL-2 and IL-15 at the level of the organism are dramatically different, as shown by work in
knockout mice: lack of IL-15 causes immune system defects, whereas lack of IL-2 causes
immune activation and severe autoimmunity. See, Waldmann, (2006) Nat Rev Immunol
6:595-601; and Ma, et al., (2006) Annu Rev Immunol 24:657-679. Both cytokines are under
tight and complex regulation at all steps of expression and secretion. The biological
differences of IL-2 and IL-15 are determined by their different production sites, their strength
of association with membrane receptor proteins termed IL-2 Receptor alpha and IL-15
Receptor alpha (IL-15R α), respectively, and the regulation of these extra receptor molecules.
IL-15 has been also reported to have a unique mechanism of action in vivo among the
common gamma chain cytokines: IL-15 functions in a complex with IL-15R α and depends
on the co-expression by the same cells of IL-15R α. See, Burkett, et al., (2004) J Exp Med
200:825-834; Burkett, et al., (2003) Proc Natl Acad Sci USA 100:4724-4729; Dubois, et al.,
(2002) Immunity 17:537-547; Sandau, et al, (2004) J Immunol 173:6537-6541; Schluns, et
al., (2004) Blood 103:988-994; Rubinstein, et al., (2006) Proc Natl Acad Sci USA 103:9166-
9171; Bergamaschi, et al., (2008) J Biol Chem 283:4189-4199. IL-15 has non-redundant
roles in the development and function of NK and intestinal intraepithelial lymphocytes
(IELs). See, Cooper, et al., (2001) Blood 97:3146-3151. It stimulates cytolytic activity,
cytokine secretion, proliferation and survival of NK cells. See, Fehniger, et al., (1999) J
Immunol 162:4511-4520; Ross, et al., (1997) Blood 89:910-918; and Carson, et al., (1994) J
Exp Med 180:1395-1403. IL-15 has a proliferative and survival effect on CD8+ memory T-
cells and naive CD8+ T-cells. See, Tan, et al., (2002) J Exp Med 195:1523-1532; Zhang, et
al., (1998) Immunity 8:591-599; Berard, et al., (2003) J Immunol 170:5018-5026; and Alves,
et al., (2003) Blood 102:2541-2546.
Several studies have evaluated the effects of IL-15 administration in vivo. CD8+
memory T-cell proliferation increased after a single dose of IL-15 in normal mice. See,
Zhang, et al., (1998) Immunity 8:591-599. Administration of IL-15 to mice enhanced the
antitumor activity after syngeneic bone marrow transplantation (BMT) and antigen-specific
primary CD8+ T-cell responses following vaccination with peptide-pulsed dendritic cells.
See, Rubinstein, et al., (2002) J Immunol 169:4928-4935; Katsanis, et al., (1996)
Transplantation 62:872-875. IL-15 also enhanced immune reconstitution after allogeneic
bone marrow transplantation. See, Alpdogan, et al., (2005) Blood 105:865-873; and Evans,
et al., (1997) Cell Immunol 179:66-73. The ability of IL-15 to promote growth, survival and
activation of key lymphocyte populations make it also an attractive candidate for supporting
growth in vitro and in vivo of cells for adoptive cell therapy. See, Rosenberg, et al., (2008)
Nat Rev Cancer 8:299-308; and Berger, et al., (2008) J Clin Invest 118:294-305.
We have demonstrated that efficient production of IL-15 requires the expression of
IL-15 and IL-15 Receptor alpha (IL-15R α) in the same cell. See, Bergamaschi, et al., (2008)
J Biol Chem 283:4189-4199. Co-production leads to intracellular association of IL-15 and
IL-15R α in the endoplasmic reticulum, stabilization of both molecules and efficient transport
to the cell surface (Figure 1). We showed that an additional critical step is the rapid cleavage
and release of the IL-15/IL-15R α complex from the cell surface, both in vitro and in vivo,
resulting in a soluble, systemically active form of IL-15/IL-15R α, in addition to the bioactive
complex on the cell surface. See, Dubois, et al., (2002) Immunity 17:537-547; Bergamaschi,
et al., (2008) J Biol Chem 283:4189-4199; and Budagian, et al., (2004) J Biol Chem
279:40368-40375. Our experiments using IL-15 complexed to a deletion mutant of IL-15R α
containing only the soluble Receptor alpha extracellular fragment demonstrated that this
complex is bioactive in vivo in the absence of any membrane-bound form.
Therefore, we proposed that IL-15R α is part of a heterodimeric IL-15 cytokine,
rather than functioning as a cytokine receptor. These results have been supported by other
investigators, and provide the basis for a better understanding of IL-15 biology. See,
Duitman, et al., (2008) Mol Cell Biol 28:4851-4861; Mortier, et al., (2008) J Exp Med
205:1213-1225. The results also provide the molecular basis to explain some intriguing
observations, including the requirement of production of IL-15 and IL-15R α from the same
cells for appropriate function in vivo. See, Sandau, et al., (2004) J Immunol 173:6537-6541;
and Koka, et al., (2003) J Exp Med 197:977-984. Such results are fully explained by our
finding that stabilization during co-expression in the same cell is required for physiological
levels of IL-15 production. It has also been reported that the cells that physiologically
express IL-15 also express IL-15R α, consistent with IL-15 production as a heterodimer in the
body. See, Dubois, et al., (2002) Immunity 17:537-547; Giri, et al., (1995) J Leukoc Biol
57:763-766; and Ruckert, et al., (2003) Eur J Immunol 33:3493-3503. Interpretation of all
data available to date suggests that the main bioactive form of IL-15 is in a complex with the
Receptor alpha either on the surface of the cells or in a soluble circulating form. It remains to
be determined whether single-chain IL-15 is produced in the body in physiologically relevant
levels and what is its exact function.
It has been previously reported that IL-15 secretion is inefficient. See, Bamford, et
al., (1998) J Immunol 160:4418-4426; Gaggero, et al., (1999) Eur J Immunol 29:1265-1274;
Kurys, et al., (2000) J Biol Chem 275:30653-30659; Onu, et al., (1997) J Immunol 158:255-
262; and Tagaya, et al., (1997) Proc Natl Acad Sci USA 94:14444-14449. We took a
systematic approach to develop IL-15 expression vectors producing high levels of bioactive
cytokine based on the observation that multiple regulatory steps during gene expression
create bottlenecks of IL-15 production. See, Jalah, et al., (2007) DNA Cell Biol 26:827-840;
and Kutzler, et al., (2005) J Immunol 175:112-123. We showed that combination of two
approaches, namely mRNA optimization (RNA/codon optimization) of the IL-15 coding
sequences and substitution of the signal peptide with other efficient secretory signals resulted
in synergistically improved expression and secretion of bioactive IL-15. See, Jalah, et al.,
(2007) DNA Cell Biol 26:827-840. Taking advantage of the stabilization of IL-15 by co-
expression with IL-15R α described above, we produced equally optimized vectors for IL-
15R α and combination vectors expressing both molecules, as well as combinations producing
only the soluble heterodimeric cytokine. The final improvement in expression of secreted IL-
was more than 1,000 fold compared to wt IL-15 cDNA, as determined by in vitro and in
vivo experiments. We have produced similar vectors for mouse, macaque and human IL-
/IL-15R α.
Two forms of interleukin-15 (IL-15) are known, containing a long signal peptide
(LSP) or a short signal peptide (SSP), respectively. The two forms are produced by
alternatively spliced mRNAs and differ only in the length of their signal peptides, the 48 aa
long signal peptide or the 21 aa short signal peptide (120, 121, 125-127). See, Onu, et al.,
(1997) J Immunol 158:255-262; Tagaya, et al., (1997) Proc Natl Acad Sci USA 94:14444-
14449; Meazza, et al., (1997) Eur J Immunol 27:1049-1054; Meazza, et al., (1996) Oncogene
12:2187-2192; and Nishimura, et al., (1998) J Immunol 160:936-942. Whereas LSP IL-15 is
secreted, SSP IL-15 remains exclusively intracellular and its function is not known. It has
been proposed that SSP IL-15 may have a regulatory function since it was detected both in
the cytoplasm and the nucleus of DNA-transfected cells. The SSP signal affects both
stability and localization of IL-15, since lower levels of the SSP isoform were detected when
the two isoforms were expressed from similar vectors. See, See, Onu, et al., (1997) J
Immunol 158:255-262; Tagaya, et al., (1997) Proc Natl Acad Sci USA 94:14444-14449; and
Bergamaschi, et al., (2009) J Immunol, 5:3064-72.
In Bergamaschi, we showed that, similar to LSP IL-15, SSP IL-15 is stabilized and
secreted efficiently upon coexpression of IL-15R α in the same cell. See, Bergamaschi, et al.,
(2009) J Immunol, supra. Co-expression of SSP IL-15 and IL-15R α in mice showed
increased plasma levels of bioactive SSP IL-15 and mobilization and expansion of NK and T
cells. Therefore, SSP IL-15 is secreted and bioactive when produced as a heterodimer with
IL-15R α in the same cell. The apparent stability of this complex both in vitro and in vivo is
lower compared to LSP IL-15/IL-15R α complex, as revealed by direct comparisons. This
results in lower production of secreted bioactive IL-15/IL-15R α. Thus, alternative splicing
may provide the cell with the ability to produce different levels of bioactive IL-15. Since
both forms of IL-15 may be produced in the same cell by alternative splicing, an additional
level of regulation is possible. We showed that when both LSP IL-15 and SSP IL-15 are
produced in the same cell they compete for the binding to IL-15R α, resulting in lower levels
of bioactive IL-15. Therefore, co-expressed SSP IL-15 acts as competitive inhibitor of LSP
IL-15. This suggests that usage of alternative splicing is an additional level of control of IL-
activity. Expression of both SSP and LSP forms of IL-15 appears to be conserved in
many mammals, suggesting that SSP may be important for expressing a form of IL-15 with
lower magnitude and duration of biological effects. The present invention is based, in part,
on the discovery that SSP IL-15, which is produced in the thymus, is important for intra-
thymic effects on lymphocyte differentiation and maturation.
BRIEF SUMMARY OF THE INVENTION
The present invention provides a use of (a) an IL-15 and a soluble IL-15Rα (IL-
/IL-15sRα) complex and (b) an IL-15 and IL-15RαFc fusion protein (IL-15/IL-15RαFc)
complex in the manufacture of a medicament for treating lymphopenia in a patient in need
thereof.
[0012a] Also described are compositions and methods that promote the maturation of T cells
in the thymus and the output or migration of mature and/or activated lymphocytes from a
central lymphoid organ to peripheral tissues by administration of IL-15. The invention is
based, in part, on the discovery that IL-15 promotes the migration of T cells out of the
thymus and subsequently to peripheral lymphoid (e.g., spleen and lymph node) and non-
lymphoid tissues (e.g., lung and liver). In some embodiments, the methods concurrently
promote the maturation of lymphocytes in the bone marrow, e.g., B cells and natural killer
(NK) cells, and their migration to peripheral lymphoid and non-lymphoid tissues.
Accordingly, described herein are methods of promoting T-cell maturation in
thymic tissue comprising contacting the thymic tissue with IL-15.
The thymic tissue can be in vivo or in vitro.
Also described are methods of promoting the migration of lymphocytes from a
central lymphoid tissue to one or more peripheral tissues in a subject in need thereof
comprising administering to the subject IL-15.
With respect to the embodiments, in some embodiments, the lymphocytes are T
cells and the central lymphoid tissue is thymus. In some embodiments, the lymphocytes are
B cells and/or NK cells and the central lymphoid tissue is bone marrow.
In some embodiments, the lymphocytes migrating from the central lymphoid tissues
are mature but not activated. In some embodiments, the lymphocytes migrating from the
central lymphoid tissues are mature and activated. In some embodiments, the T cells
migrating from the thymus are mature single positive (CD4+ or CD8+) T cells. The T cells
induced to leave the thymus may be activated or not activated.
Also described are methods for preventing, treating, alleviating, reducing and/or
inhibiting lymphopenia or depletion of lymphocytes in peripheral tissues by administration of
IL-15. Also described are methods for promoting the repopulation of peripheral tissues that
have been depleted of lymphocytes and accelerating the recovery from lymphocyte depletion
of peripheral tissues by the administration of IL-15.
Accordingly, in one aspect, described are methods of preventing, reducing or
inhibiting lymphopenia or depletion of lymphocytes in peripheral tissues in an individual in
need thereof comprising systemically administering IL-15 to the individual.
In some embodiments, the lymphopenia or lymphocyte depletion of peripheral
tissues is drug-induced. For example, the individual may be receiving anticancer drugs or
antiviral drugs, or radiation therapy that induces lymphopenia or lymphocyte depletion of
peripheral tissues.
In some embodiments, the IL-15 is co-administered with an agent that causes
depletion of lymphocytes in peripheral tissues, e.g., an anticancer or an antiviral agent. In
some embodiments, the IL-15 is co-administered with radiation therapy.
In a related aspect, described are methods of promoting or accelerating the
repopulation of lymphocytes in peripheral tissues in an individual in need thereof comprising
systemically administering IL-15 to the individual.
In some embodiments, the systemic administration of IL-15 prevents or reduces the
depletion of or promotes or accelerates the repopulation of one or more of T cells, B cells or
NK cells. In some embodiments, the systemic administration of IL-15 prevents or reduces
the depletion of or promotes or accelerates the repopulation of one or more of CD4+ T cells
or CD8+ T cells.
In some embodiments of the methods described herein, the subject or patient is a
mammal. In some embodiments, the subject or patient is a human.
When administered in vivo the IL-15 can be administered systemically, including
without limitation, enterally (i.e., orally) or parenterally, e.g., intravenously, intramuscularly,
subcutaneously, intradermally, intranasally, or inhalationally. In some embodiments, the IL-
is administered locally, for example, intrathymically.
Systemic administration is at a dose that is sufficient to maintain IL-15 at
supraphysiologic levels. For example, IL-15 DNA or protein can be administered at a dose
sufficient to achieve plasma levels of IL-15 of about 1 to 1000 ng/ml, for example, plasma
levels of IL-15 of about 10 to 1000 ng/ml. The IL-15 and IL-15R α can be delivered in
equimolar amounts. Such a range of IL-15 plasma concentrations can be achieved, e.g., after
intramuscular electroporation of about 0.1 mg IL-15/IL-15R α expressing DNA plasmid per
kg body weight. Alternatively, an IL-15/IL-15R α protein complex can be administered at a
dose of about 0.01 to 0.5 mg/kg. IL-15/IL-15R α polypeptides can be administered, e.g.,
subcutaneously, intramuscularly, intraperitoneally or intravenously. See, e.g., Rosati, et al.,
Vaccine (2008) 26:5223-5229.
The IL-15 can be administered as a polypeptide or as a polynucleotide encoding IL-
. In some embodiments, the IL-15 is co-administered with IL-15R α, e.g., as a heterodimer.
The co-administered IL-15R α can be a polypeptide or a polynucleotide encoding IL-15R α.
The co-administered IL-15R α can be in the same or different form as the IL-15. For
example, both the IL-15 and the IL-15R α can be administered as polypeptides or as one or
more polynucleotides encoding IL-15 and/or IL15R α. Alternatively, one of the IL-15 and the
IL15R α can be administered as a polypeptide and the other as a polynucleotide encoding
either IL-15 or IL-15R α. In some embodiments, the IL-15R α is a soluble IL-15R α. In some
embodiments, the IL-15R α may be administered in the form of an Fc fusion protein or a
polynucleotide that encodes an Fc fusion protein.
In some embodiments, the IL-15 and the IL-15R α are concurrently administered as
one or more polynucleotides encoding IL-15 and/or IL-15R α. The polynucleotide encoding
IL-15 and the polynucleotide encoding IL-15R α can be on the same or separate vectors, for
example, single or multiple plasmid vectors. In some embodiments, the IL-15 and the IL-
15R α polynucleotides are concurrently expressed from a plasmid vector of SEQ ID NO:13,
SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, or SEQ ID NO: 19.
In some embodiments, the polynucleotides encoding one or both of IL-15 and the
IL-15R α are wild-type coding sequences. In some embodiments, the polynucleotide
encoding IL-15 shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
100% sequence identity to SEQ ID NO:1. In some embodiments, the polynucleotide
encoding IL-15R α shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or
100% sequence identity to SEQ ID NO:5 or SEQ ID NO:7.
In some embodiments, the polynucleotides encoding one or both of IL-15 and the
IL-15R α are codon optimized for improved expression over the wild-type coding sequences.
In some embodiments, the polynucleotide encoding IL-15 shares at least 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:3 or SEQ
ID NO:4. In some embodiments, the polynucleotide encoding IL-15R α shares at least 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID
NO:9 or SEQ ID NO:11.
When expressed from a polynucleotide encoding IL-15, the coding sequence can
have a native or a heterologous signal peptide. In some embodiments, the signal peptide is a
native IL-15 signal peptide, for example, the native IL-15 long signal peptide or the native
IL-15 short signal peptide. In some embodiments, the signal peptide is a heterologous signal
peptide, for example, a signal peptide from granulocyte-macrophage colony stimulating
factor (GM-CSF), tissue plasminogen activator (tPA), growth hormone, or an
immunoglobulin.
In some embodiments, the peripheral tissue is a peripheral lymphoid tissue,
including without limitation, spleen, lymph node, mucosal-associated lymphoid tissues
(MALT), e.g., tonsils and/or gut-associated lymphoid tissues (GALT), including Peyer’s
patches.
In some embodiments, the peripheral tissue is a peripheral non-lymphoid tissue,
e.g., lung, liver, kidney, heart, skin, etc.
Preferably, the IL-15 is administered without an antigen, i.e., is not co-administered
with an antigen.
In a related aspect, described is a DNA vector encoding IL-15 and IL-15R α for use
in promoting lymphocyte mobilization from central lymphoid tissue and migration to
peripheral tissues.
In another aspect, described is IL-15/IL-15R α for use in promoting lymphocyte
mobilization from central lymphoid tissue and migration to peripheral tissues.
In a related aspect, described is a DNA vector encoding IL-15 and IL-15R α for use
in promoting the maturation and export of T cells from the thymus to peripheral tissues,
including peripheral lymphoid and non-lymphoid tissues.
In another aspect, described are IL-15/IL-15R α polypeptide complexes for use in
promoting the maturation and export of T cells from the thymus to peripheral tissues,
including peripheral lymphoid and non-lymphoid tissues.
In a related aspect, described is a DNA vector encoding IL-15 and IL-15R α for use
in promoting repopulation of depleted lymphocytes in peripheral tissues and/or preventing,
reducing and/or inhibiting lymphopenia.
In another aspect, described are IL-15/IL-15R α polypeptide complexes for use in
promoting repopulation of depleted lymphocytes in peripheral tissues and/or preventing,
reducing and/or inhibiting lymphopenia.
In another aspect, described are stable cell lines that express IL-15/IL-15Rα
polypeptides. In some embodiments, the stable cell line expresses IL-15/IL-15Rα in the
form of a fusion protein. In some embodiments, the stable cell lines produce IL-15 and IL-
15Rα as different molecules. In some embodiments, the stable cell lines produce IL-15 and
secreted IL-15Rα deletions that lack the transmembrane anchor portion of the receptor. In
some embodiments the stable cell lines produce IL-15 and fusions of IL15Rα to the an
immunoglobulin Fc region. In some embodiments the stable cell lines produce IL-15 and IL-
15Rα fusions to polypeptides able to direct binding of the fusion to the cell surface of
specific cell types. In some embodiments the stable cell lines produce IL-15 and IL-15Rα
fusions to polypeptides able to direct multimerization of the fusion.
Further embodiments are as described herein.
DEFINITIONS
The term “central lymphoid tissue” or “central lymphoid organ” refers to
specialized lymphoid tissues where the production of new lymphocytes, or lymphopoiesis,
takes place. For example, T cells develop and mature in the thymus or thymic tissue. B cells
and natural killer (NK) cells develop in bone marrow tissue. See, e.g., Chapter 7 of Janeway,
et al., Immunobiology, 2001, Garland Publishing, New York.
The term “peripheral lymphoid tissue” or “peripheral lymphoid organ” refers to
peripheral tissues of highly organized architecture, with distinct areas of B cells and T cells.
Newly produced lymphocytes leave the central lymphoid tissues, and are carried in the blood
to the peripheral lymphoid tissues. Exemplary peripheral lymphoid tissues or organs include
the spleen, lymph nodes, mucosal-associated lymphoid tissues (MALT), e.g., tonsils and gut-
associated lymphoid tissues (GALT), including Peyer’s patches.
The term “mature lymphocyte” refers to a lymphocyte that is undergone selection
and development to maturity in the central lymphoid tissue sufficient to circulate to
peripheral lymphoid tissues. With respect to T cells, a mature T cell is characterized by the
expression of either CD4 or CD8, but not both (i.e., they are single positive), and expression
of CD3. With respect to B cells, a mature B cell is characterized by VDJ rearranged
immunoglobulin heavy chain gene, VJ rearranged immunoglobulin light chain gene, and the
surface expression of IgD and/or IgM. The mature B cell may also express CD19 and the IL-
7 receptor on the cell surface.
The term “activated lymphocyte” refers to lymphocytes that have recognized an
antigen bound to a MHC molecule and the simultaneous delivery of a co-stimulatory signal
by a specialized antigen-presenting cell. Activation of lymphocytes changes the expression
of several cell-surface molecules.
With respect to T cells, resting naive T cells express L-selectin, and low levels of
other adhesion molecules such as CD2 and LFA-1. Upon activation of the T cell, expression
of L-selectin is lost and, instead, increased amounts of the integrin VLA-4 are expressed.
Activated T cells also express higher densities of the adhesion molecules CD2 and LFA-1,
increasing the avidity of the interaction of the activated T cell with potential target cells, and
higher densities of the adhesion molecule CD44. Finally, the isoform of the CD45 molecule
expressed by activated cells changes, by alternative splicing of the RNA transcript of the
CD45 gene, so that activated T cells express the CD45RO isoform that associates with the T-
cell receptor and CD4. Also, with respect to cytokine production, resting T cells produce
little or no IL-2 and the β and γ subunits of the IL-2 receptor. In contrast, activated T cells
produce significant amounts IL-2 along with the α chain of the IL-2 receptor.
With respect to B cells, activated B cells have undergone isotype switching and
secrete immunoglobulin. Naive B cells express cell-surface IgM and IgD immunoglobulin
isotypes. In contrast, activated or memory B cells express and secrete IgG, IgA or IgE
immunoglobulin isotypes.
The terms “output” or “migration” from a central lymphoid tissue refers to
migration or export of mature lymphocytes from a central lymphocyte tissue to a peripheral
tissue, including lymphoid and non-lymphoid peripheral tissues. Output includes the
migration of mature T cells from the thymus and the migration of mature B cells and NK
cells from the bone marrow.
The terms “treating” and “treatment” refer to delaying the onset of, retarding or
reversing the progress of, or alleviating or preventing either the disease or condition to which
the term applies, or one or more symptoms of such disease or condition.
The terms “lymphopenia” or “lymphocytopenia” or “lymphocytic leucopenia”
interchangeably refer to an abnormally small number of lymphocytes in the circulating blood
or in peripheral circulation. Quantitatively, lymphopenia can be described by various cutoffs.
In some embodiments, a patient is suffering from lymphopenia when their circulating blood
total lymphocyte count falls below about 600/mm . In some embodiments, a patient
suffering from lymphopenia has less than about 2000/ μL total circulating lymphocytes at
birth, less than about 4500/ μL total circulating lymphocytes at about age 9 months, or less
than about 1000/ μL total circulating lymphocytes patients older than about 9 months
(children and adults). Lymphocytopenia has a wide range of possible causes, including viral
(e.g., HIV infection), bacterial (e.g., active tuberculosis infection), and fungal infections;
chronic failure of the right ventricle of the heart, Hodgkin’s disease and cancers of the
lymphatic system, leukemia, a leak or rupture in the thoracic duct, side effects of prescription
medications including anticancer agents, antiviral agents, and glucocorticoids, malnutrition
resulting from diets that are low in protein, radiation therapy, uremia, autoimmune disorders,
immune deficiency syndromes, high stress levels, and trauma. Lymphopenia may also be of
unknown etiology (i.e., idiopathic lymphopenia). Peripheral circulation of all types of
lymphocytes or subpopulations of lymphocytes (e.g., CD4+ T cells) may be depleted or
abnormally low in a patient suffering from lymphopenia. See, e.g., The Merck Manual, 18
Edition, 2006, Merck & Co.
The term “native mammalian interleukin-15 (IL-15)” refers to any naturally
occurring interleukin-15 nucleic acid and amino acid sequences of the IL-15 from a
mammalian species. Those of skill in the art will appreciate that interleukin-15 nucleic acid
and amino acid sequences are publicly available in gene databases, for example, GenBank
through the National Center for Biotechnological Information on the worldwide web at
ncbi.nlm.nih.gov. Exemplified native mammalian IL-15 nucleic acid or amino acid
sequences can be from, for example, human, primate, canine, feline, porcine, equine, bovine,
ovine, rodentia, murine, rat, hamster, guinea pig, etc. Accession numbers for exemplified
native mammalian IL-15 nucleic acid sequences include NM_172174.2 (human
preproprotein); NM_172175 (human); NM_000585.3 (human preproprotein); U19843
(macaque); DQ021912 (macaque); AB000555 (macaque); NM_214390 (porcine);
DQ152967 (ovine); NM_174090 (bovine); NM_008357 (murine); NM_013129 (rattus);
DQ083522 (water buffalo); XM_844053 (canine); DQ157452 (lagomorpha); and
NM_001009207 (feline). Accession numbers for exemplified native mammalian IL-15
amino acid sequences include NP_000576.1 (human preproprotein); NP_751914 (human
preproprotein); CAG46804 (human); CAG46777 (human); AAB60398 (macaque);
AAY45895 (macaque); NP_999555 (porcine); NP_776515 (bovine); AAY83832 (water
buffalo); ABB02300 (ovine); XP_849146 (canine); NP_001009207 (feline); NP_037261
(rattus); and NP_032383 (murine).
The term “interleukin-15” or “IL-15” refers to a polypeptide that has at least 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a native
mammalian IL-15 amino acid sequence, or a nucleotide encoding such a polypeptide, is
biologically active, meaning the mutated protein (“mutein”) has functionality similar (75% or
greater) to that of a native IL-15 protein in at least one functional assay. Functionally, IL-15
is a cytokine that regulates T cell and natural killer cell activation and proliferation. IL-15
and IL-2 share many biological activities, including binding to CD122, the IL-2 β/IL-15 β
receptor subunit. The number of CD8+ memory cells is controlled by a balance between this
IL-15 and IL-2. IL-15 induces the activation of JAK kinases, as well as the phosphorylation
and activation of transcription activators STAT3, STAT5, and STAT6. IL-15 also increases
the expression of apoptosis inhibitor BCL2L1/BCL-x(L), possibly through the transcription
activation activity of STAT6, and thus prevents apoptosis. Two alternatively spliced
transcript variants of the IL-15 gene encoding the same mature protein have been reported.
Exemplified functional assays of an IL-15 polypeptide include proliferation of T-cells (see,
for example, Montes, et al., Clin Exp Immunol (2005) 142:292), and activation of NK cells,
macrophages and neutrophils. Methods for isolation of particular immune cell
subpopulations and detection of proliferation (i.e., H-thymidine incorporation) are well
known in the art. Cell-mediated cellular cytotoxicity assays can be used to measure NK cell,
macrophage and neutrophil activation. Cell-mediated cellular cytotoxicity assays, including
release of isotopes ( Cr), dyes (e.g., tetrazolium, neutral red) or enzymes, are also well
known in the art, with commercially available kits (Oxford Biomedical Research, Oxford, M;
Cambrex, Walkersville, MD; Invitrogen, Carlsbad, CA). IL-15 has also been shown to inhibit
Fas mediated apoptosis (see, Demirci and Li, Cell Mol Immunol (2004) 1:123). Apoptosis
assays, including for example, TUNEL assays and annexin V assays, are well known in the
art with commercially available kits (R&D Systems, Minneapolis, MN). See also, Coligan,
et al., Current Methods in Immunology, 1991-2006, John Wiley & Sons.
The term “native mammalian interleukin-15 Receptor alpha (IL15R α)” refers to any
naturally occurring interleukin-15 receptor alpha nucleic acid and amino acid sequences of
the IL-15 receptor alpha from a mammalian species. Those of skill in the art will appreciate
that interleukin-15 receptor alpha nucleic acid and amino acid sequences are publicly
available in gene databases, for example, GenBank through the National Center for
Biotechnological Information on the worldwide web at ncbi.nlm.nih.gov. Exemplified native
mammalian IL-15 receptor alpha nucleic acid or amino acid sequences can be from, for
example, human, primate, canine, feline, porcine, equine, bovine, ovine, rodentia, murine, rat,
hamster, guinea pig, etc. Accession numbers for exemplified native mammalian IL-15
nucleic acid sequences include NM_172200.1 (human isoform 2); and NM_002189.2 (human
isoform 1 precursor). Accession numbers for exemplified native mammalian IL-15 amino
acid sequences include NP_751950.1 (human isoform 2); and NP_002180.1 (human isoform
1 precursor).
The term “interleukin-15 receptor alpha” or “IL15R α” refers to a polypeptide that
has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a
native mammalian IL15Ra amino acid sequence, or a nucleotide encoding such a
polypeptide, is biologically active, meaning the mutated protein (“mutein”) has functionality
similar (75% or greater) to that of a native IL15R α protein in at least one functional assay.
IL15R α is a cytokine receptor that specifically binds IL15 with high affinity. One functional
assay is specific binding to a native IL-15 protein.
The term “soluble IL-15 Receptor alpha” or “sIL-15 α” refers to forms of IL-15
Receptor alpha lacking the transmembrane anchor portion of the receptor and thus able to be
secreted out of the cell without being anchored to the plasma membrane. Exemplary sIL-15 α
include aa 31-205 and aa31-185 of the native IL-15 Receptor alpha.
An “IL-15R α Fc fusion” or an “IL-15Rα fused to an Fc region” as used herein
refers to forms of IL-15Rα in which the protein is fused to one or more domains of an Fc
region of an immunoglobulin, typically of an IgG immunoglobulin. The Fc region comprises
the CH2 and CH3 domains of the IgG heavy chain and the hinge region. The hinge serves as
a flexible spacer between the two parts of the Fc-Fusion protein, allowing each part of the
molecule to function independently. The use of Fc fusions is known in the art (see, e.g., U.S.
Patent Nos. 7,754,855; 5,480,981; 5,808,029; Wo7/23614; Wo98/28427 and references cited
therein. Fc fusion proteins can include variant Fc molecules (e.g., as described in U.S. Patent
No. 7,732,570). Fc fusion proteins can be soluble in the plasma or can associate to the cell
surface of cells having specific Fc receptors.
The term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides and
polymers thereof in either single- or double-stranded form. The term encompasses nucleic
acids containing known nucleotide analogs or modified backbone residues or linkages, which
are synthetic, naturally occurring, and non-naturally occurring, which have similar binding
properties as the reference nucleic acid, and which are metabolized in a manner similar to the
reference nucleotides. Examples of such analogs include, without limitation,
phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates,
2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).
Unless otherwise indicated, a particular nucleic acid sequence also implicitly
encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions)
and complementary sequences, as well as the sequence explicitly indicated. Degenerate
codon substitutions can be achieved by generating sequences in which the third position of
one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine
residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem.
260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The term nucleic
acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
Degenerate codon substitutions for naturally occurring amino acids are in Table 1.
TABLE 1
st nd rd
1 position 2 position 3 position
(5 ′ end) U(T) C A G (3 ′ end)
U(T) Phe Ser Tyr Cys U(T)
Phe Ser Tyr Cys C
Leu Ser STOP STOP A
Leu Ser STOP Trp G
C Leu Pro His Arg U(T)
Leu Pro His Arg C
Leu Pro Gln Arg A
Leu Pro Gln Arg G
A Ile Thr Asn Ser U(T)
Ile Thr Asn Ser C
Ile Thr Lys Arg A
Met Thr Lys Arg G
st nd rd
1 position 2 position 3 position
(5 ′ end) (3 ′ end)
U(T) C A G
G Val Ala Asp Gly U(T)
Val Ala Asp Gly C
Val Ala Glu Gly A
Val Ala Glu Gly G
The terms “identical” or percent “identity,” in the context of two or more nucleic
acids or polypeptide sequences, refer to two or more sequences or subsequences that are the
same or have a specified percentage of amino acid residues or nucleotides that are the same
(i.e., about 70% identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99%, or higher identity over a specified region (e.g., of a IL-15 or IL-15R α
sequence), when compared and aligned for maximum correspondence over a comparison
window or designated region) as measured using a BLAST or BLAST 2.0 sequence
comparison algorithms with default parameters described below, or by manual alignment and
visual inspection (see, e.g., NCBI web site or the like). Such sequences are then said to be
“substantially identical.” This definition also refers to, or can be applied to, the compliment
of a test sequence. The definition also includes sequences that have deletions and/or
additions, as well as those that have substitutions. As described below, the preferred
algorithms can account for gaps and the like. Preferably, identity exists over a region that is
at least about 25, 50, 75, 100, 150, 200 amino acids or nucleotides in length, and oftentimes
over a region that is 225, 250, 300, 350, 400, 450, 500 amino acids or nucleotides in length or
over the full-length of am amino acid or nucleic acid sequences.
For sequence comparison, typically one sequence acts as a reference sequence, to
which test sequences are compared (here, an entire “native mammalian” IL-15 amino acid or
nucleic acid sequence). When using a sequence comparison algorithm, test and reference
sequences are entered into a computer, subsequence coordinates are designated, if necessary,
and sequence algorithm program parameters are designated. Preferably, default program
parameters can be used, or alternative parameters can be designated. The sequence
comparison algorithm then calculates the percent sequence identities for the test sequences
relative to the reference sequence, based on the program parameters.
A preferred example of algorithm that is suitable for determining percent sequence
identity and sequence similarity are the BLAST algorithms, which are described in Altschul
et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410
(1990), respectively. BLAST software is publicly available through the National Center for
Biotechnology Information on the worldwide web at ncbi.nlm.nih.gov/. Both default
parameters or other non-default parameters can be used. The BLASTN program (for
nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10,
M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP
program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62
scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989))
alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.
The term “GC content” refers to the percentage of a nucleic acid sequence
comprised of deoxyguanosine (G) and/or deoxycytidine (C) deoxyribonucleosides, or
guanosine (G) and/or cytidine (C) ribonucleoside residues.
The term “operably linked” refers to a functional linkage between a first nucleic
acid sequence and a second nucleic acid sequence, such that the first and second nucleic acid
sequences are transcribed into a single nucleic acid sequence. Operably linked nucleic acid
sequences need not be physically adjacent to each other. The term “operably linked” also
refers to a functional linkage between a nucleic acid expression control sequence (such as a
promoter, or array of transcription factor binding sites) and a transcribable nucleic acid
sequence, wherein the expression control sequence directs transcription of the nucleic acid
corresponding to the transcribable sequence.
Amino acids can be referred to herein by either their commonly known three letter
symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical
Nomenclature Commission. Nucleotides, likewise, can be referred to by their commonly
accepted single-letter codes.
“Conservatively modified variants” as used herein applies to amino acid sequences.
One of skill will recognize that individual substitutions, deletions or additions to a nucleic
acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino
acid or a small percentage of amino acids in the encoded sequence is a “conservatively
modified variant” where the alteration results in the substitution of an amino acid with a
chemically similar amino acid. Conservative substitution tables providing functionally
similar amino acids are well known in the art. Such conservatively modified variants are in
addition to and do not exclude polymorphic variants, interspecies homologs, and alleles
described herein.
The following eight groups each contain amino acids that are conservative
substitutions for one another:
1) Alanine (A), Glycine (G);
2) Aspartic acid (D), Glutamic acid (E);
3) Asparagine (N), Glutamine (Q);
4) Arginine (R), Lysine (K);
) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
7) Serine (S), Threonine (T); and
8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
The terms “mammal” or “mammalian” refer to any animal within the taxonomic
classification mammalia. A mammal can refer to a human or a non-human primate. A
mammal can refer to a domestic animal, including for example, canine, feline, rodentia,
including lagomorpha, murine, rattus, Cricetinae (hamsters), etc. A mammal can refer to an
agricultural animal, including for example, bovine, ovine, porcine, equine, etc.
The term “therapeutically effective amount” refers to the dose of a therapeutic agent
or agents sufficient to achieve the intended therapeutic effect with minimal or no undesirable
side effects. A therapeutically effective amount can be readily determined by a skilled
physician, e.g., by first administering a low dose of the pharmacological agent(s) and then
incrementally increasing the dose until the desired therapeutic effect is achieved with
minimal or no undesirable side effects.
The term “supraphysiologic levels” refers to levels of IL-15 in a particular tissue,
e.g., blood, plasma, serum, thymus, that are above naturally occurring physiologic levels.
Supraphysiologic levels of IL-15 in a tissue can also be achieved when the concentration of
IL-15 in that tissue is sustained above naturally occurring levels for an extended period of
time, e.g.., for consecutive days or weeks or for the duration of therapeutic treatment. For
example, IL-15 DNA or protein can be administered at a dose sufficient to achieve plasma
levels of IL-15 of about 1 to 1000 ng/ml, for example, plasma levels of IL-15 of about 10 to
1000 ng/ml. The IL-15 and IL-15R α can be delivered in equimolar amounts. Alternatively,
an IL-15/IL-15R α protein complex can be administered at a dose of about 0.01 to 0.5 mg/kg.
The term “co-administer” refers to the presence of two pharmacological agents, e.g.,
IL-15 and IL-15R α, in the blood at the same time. The two pharmacological agents can be
administered concurrently or sequentially.
The term “consisting essentially of” refers to administration of the
pharmacologically active agents expressly recited, e.g., IL-15 and IL-15R α, and excludes
pharmacologically active agents not expressly recited, e.g., an antigen. The term consisting
essentially of does not exclude pharmacologically inactive or inert agents, e.g.,
physiologically acceptable carriers or excipients.
[0073a] The term “comprising” as used in this specification and claims means “consisting at
least in part of”. When interpreting statements in this specification, and claims which include
the term “comprising”, it is to be understood that other features that are additional to the
features prefaced by this term in each statement or claim may also be present. Related terms
such as “comprise” and “comprised” are to be interpreted in similar manner.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates a schematic of the mutual stabilization of IL-15 and IL-15 α.
Figure 2 illustrates the effects of systemic co-administration of polynucleotides
expressing IL-15 and IL-15R α on spleen weight (top panel), thymus weight (middle panel)
and percentage of lymphocytes in the bone marrow (bottom panel).
Figure 3 illustrates the effects of systemic co-administration of polynucleotides
expressing IL-15 and IL-15R α on T cell maturation in the thymus. Double positive
CD4+CD8+ T cells are decreased with a concomitant increase in CD3high single positive T
cells (i.e., CD4+ or CD8+ T cells).
Figure 4 illustrates the migration of dividing carboxyfluorescein succinimidyl ester
(“CFSE”)-loaded thymocytes to the lung in ILtreated and untreated control mice (upper
panels). The lower panels show increased expression of CD122 (IL-2R β/IL-15R β) on
lymphocytes, e.g., total T cells and CD+ T cells, in the lung.
Figure 5 illustrates lymphocyte reconstitution in lung tissue of IL-15 knock-out
(KO) mice treated with plasmid DNA encoding IL-15/IL-15R α compared to untreated
control KO mice.
Figure 6 provides a schematic of the time course of a lymphodepletion experiment.
Figure 7 illustrates spleen weight over time after cyclophosphamide (Cyp) and Cyp
+ IL-15/IL-15R α administration.
Figure 8 illustrates the increase in lung NK cells after Cyp administration.
Figure 9 illustrates the increase in lung T cells in the presence of IL-15/IL-15R α.
Figure 10 illustrates that CD8+ T cells partially recover after IL-15/IL-15R α
administration.
Figure 11 illustrates the increase in lung CD8+ T cells in the presence of IL-15/IL-
15R α as reflected in the change of the ratio of CD8+ to CD4+ T cells after IL-15
administration.
Figure 12 illustrates a T cell analysis in the spleen after Cyp and IL-15/IL-15R α
administration.
Figure 13 illustrates the full recovery of bone marrow T cells after IL-15/IL-15R α
administration.
Figure 14 illustrates the IL-15/IL-15Rα treatment protocol for lymphopenic mice
used in Example 3.
Figure 15 illustrates that a single administration of IL-15/IL-15sRα-encoding DNA
is sufficient for the complete recovery of NK cells in spleen and lung 5 days after DNA
injection.
Figure 16 illustrates that IL-15/IL-15sRα administration promotes the recovery of
CD8 T cells within 10 days after treatment, without significantly affecting the recovery of
CD4 T cells.
Figure 17 illustrates that high levels of circulating IL-15/IL-15sRα promote a
transient increase in the Teffector/Treg ratio after lymphoablation.
Figure 18 illustrates IL-15 levels in serum following hydrodynamic delivery of
DNA vectors expressing different forms of IL-15.
Figure 19 illustrates CD25 expression on the surface of spleen T cells after IL-
/IL-15Rα DNA delivery.
Figure 20 illustrates expression of CD62L on the surface of spleen T cells after IL-
/IL-15Rα DNA delivery.
Figure 21 illustrates express of CD44 on the surface of spleen T cells after IL-
/IL-5Rα DNA delivery.
Figure 22 illustrates a protocol (Example 5) for administration of purified IL-15/IL-
15sRα in vivo.
Figure 23 illustrates that purified IL-15/IL-15Rα is bioactive in vivo.
DETAILED DESCRIPTION
1. Introduction
The present disclosure is based, in part, on the surprising discovery that subjecting
thymic tissue to supraphysiological levels of IL-15 promotes the maturation of T cells in the
thymus from double positive CD4+CD8+ T cells to single positive (i.e., CD4+ or CD8+)
CD3high T cells, decreases the frequency of apoptotic thymocytes, and increases the
migration of mature T cells from the thymus to peripheral tissues, including lymphoid and
non-lymphoid peripheral tissues.
The present disclosure is further based, in part, on the surprising discovery that
systemic administration of supraphysiological levels of IL-15 promotes the maturation and
export of lymphocytes from central lymphoid tissues (e.g., in the thymus and bone marrow)
to peripheral tissues, including lymphoid and non-lymphoid peripheral tissues.
2. Methods of Promoting Maturation of Lymphocytes in a Central Lymphoid Organ
and the Migration of the Lymphocytes to Peripheral Tissues
The present disclosure describes methods of promoting T cell maturation in the
thymus, decreasing apoptosis of T cells in the thymus and promoting migration or output of
mature T cells from the thymus, by contacting the thymus tissue with supraphysiological
levels of IL-15. The thymic tissue can be in vivo or in vitro.
When the IL-15 is administered in vivo, it is provided to a subject or patient or
individual in need thereof. The subject can be any mammal. In some embodiments, the
mammal is a human or a non-human primate. Subjects who will benefit from the present
methods have a deficiency of mature thymocytes and/or other lymphocytes in peripheral
tissues, including lymphoid and non-lymphoid peripheral tissues. In some embodiments, the
subject is immunodeficient or has lymphopenia. In some embodiments, the subject has a
drug-induced immunodeficiency, e.g., due to anticancer drugs. In some embodiments, the
subject has an immunodeficiency secondary to a disease, e.g., HIV infection. In some
embodiments, the subject may have a genetic mutation that results in a non-functional IL-15
or non-functional IL-15 receptor subunit (e.g., IL-15R α, IL-15R β, or IL-15R γ).
Sustained exposure of thymic tissue to supraphysiological levels of IL-15 promotes
the maturation of double positive T cells. IL-15 promotes the terminal differentiation of the
thymocytes to single positive T cells expressing either CD4 or CD8. The mature T cells also
may express CD122 (also known as the beta subunit of IL-2/IL-15 receptor). The mature T
cells may also express high levels of the CD3 surface protein. ILinduced maturation of T
cells also corresponds to a reduction in the frequency of immature T cells that undergo
apoptosis. By contacting the thymic tissue with supraphysiologic levels of IL-15, the
CD4+CD8+ double positive and CD3low T cells can be substantially eliminated as the cells
mature into single positive CD3high T cells. After exposure to supraphysiologic levels of IL-
, at least 60%, 70%, 80%, 90%, 95% or more of the T cells are CD4+ or CD8+ single
positive CD3high T cells.
ILinduced maturation of T cells in thymus tissue also promotes the migration of
the mature T cells to the peripheral tissues, including lymphoid and non-lymphoid peripheral
tissues. The mature T cells leaving the thymus may or may not be activated. For example,
after about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days exposure to supraphysiologic levels of IL-15,
the thymus organ may have decreased in size, e.g., by at least about 30%, 40%, 50%, or
more, due to ILinduced thymic output.
Systemic administration of supraphysiologic levels of IL-15, e.g., sustained over the
course of e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days, also promotes the maturation and
migration of lymphocytes, including NK cells, from bone marrow. For example, after about
2, 3, 4, 5, 6, 7, 8, 9, 10 or more days exposure to supraphysiologic levels of IL-15, the
percentage of lymphocytes in the bone marrow may have decreased, e.g., by at least about
50%, 60%, 70%, 80%, or more, due to ILinduced lymphocyte output from bone marrow.
At the same time that the number of lymphocytes decrease in the central lymphoid
tissues, i.e., in the thymus and bone marrow, the number of lymphocytes in peripheral
lymphoid tissues, e.g., spleen, lymph node, mucosal-associated lymphoid tissues (MALT),
e.g., tonsils and/or gut-associated lymphoid tissues (GALT), including Peyer’s patches,
increases. Furthermore, the number of lymphocytes in peripheral non-lymphoid tissues,
including the lung, liver, kidney, skin, and other tissues, also increases. In some
embodiments, the administration of supraphysiologic levels of IL-15 increases the number of
lymphocytes, including T cells, B cells and NK cells, in the blood.
3. Methods of treating lymphopenia
As explained above, in one aspect, the invention is based on the discovery that
systemic administration of supraphysiological levels of IL-15 promotes the maturation and
export of lymphocytes from central lymphoid tissues (e.g., in the thymus and bone marrow)
to peripheral tissues, including lymphoid and non-lymphoid peripheral tissues.
Accordingly, described herein are methods for preventing, reducing and inhibiting
the depletion of lymphocytes, including T cells, B cells and natural killer (NK) cells, in
peripheral circulation or tissues by systemic administration of IL-15 to a subject in need
thereof. Also described are methods for accelerating the recovery from and shortening the
time period of depletion of lymphocytes, including T cells, B cells and natural killer (NK)
cells, in peripheral circulation or tissues by systemic administration of IL-15 to a subject in
need thereof.
The subject, patient or individual can be any mammal. In some embodiments, the
mammal is a human or a non-human primate. In some embodiments, the individual is a
domestic mammal (e.g., a canine or feline), a laboratory mammal (e.g., a mouse, a rat, a
rabbit, a hamster), or an agricultural mammal (e.g., a bovine, a porcine, a ovine, an equine).
Subjects who will benefit from the present methods either already have or will have (e.g., as
a result of a course of drug treatment) a deficiency of mature lymphocytes in peripheral
circulation or tissues, including lymphoid and non-lymphoid peripheral tissues. In some
embodiments, the subject is immunodeficient or has lymphopenia. For the purposes of
treatment, the patient is already suffering abnormally low levels of circulating lymphocytes.
For the purposes of prevention, the patient may have normal levels of peripheral lymphocytes
and is likely to experience lymphodepletion, e.g., as a result of a chemotherapeutic treatment.
Standards for diagnosing lymphopenia are known in the art, and can be made by
any trained physician. In some embodiments, the patient has a circulating blood total
lymphocyte count that is below about 600/mm . In some embodiments, the patient has a
circulating blood total lymphocyte count that is less than about 2000/ μL total circulating
lymphocytes at birth, less than about 4500/ μL total circulating lymphocytes at about age 9
months, or less than about 1000/ μL total circulating lymphocytes patients older than about 9
months (children and adults). See, e.g., The Merck Manual, 18th Edition, 2006, Merck & Co.
The origins or etiology of the depletion or abnormally low can be for any reason.
Lymphocytopenia has a wide range of possible causes, including viral (e.g., HIV infection),
bacterial (e.g., active tuberculosis infection), and fungal infections; chronic failure of the
right ventricle of the heart, Hodgkin’s disease and cancers of the lymphatic system, leukemia,
a leak or rupture in the thoracic duct, side effects of prescription medications including
anticancer agents, antiviral agents, and glucocorticoids, malnutrition resulting from diets that
are low in protein, radiation therapy, uremia, autoimmune disorders, immune deficiency
syndromes, high stress levels, and trauma. The lymphopenia may also be of unknown
etiology (i.e., idiopathic lymphopenia).
The lymphocyte depletion may involve total lymphocytes (e.g., T cells, B cells, and
NK cells, etc.), or may only involve a subpopulation of total lymphocytes (one or more of
T cells, CD4+ T cells, CD8+ T cells, B cells, NK cells).
In some embodiments, the patient has a disease that causes depletion of peripheral
circulating lymphocytes. For example, the patient may suffer from a cancer, including
Hodgkin’s disease and cancers of the lymphatic system, leukemia; a viral infection, including
HIV or hepatitis virus. In some embodiments, the patient is receiving chemotherapy, e.g., an
anticancer agent, an antiviral or antiretroviral agent, or a glucocorticoid, that causes depletion
of peripheral circulating lymphocytes. Exemplary pharmacological agents that can cause
lymphodepletion include without limitation vinblastine, fludarabine, aclarubicin,
doxorubicin, exemestane, alefacept, alemtuzumab, chloramphenicol, pamidronate, idarubicin
and cyclophosphamide.
In some embodiments, the subject may have a genetic mutation that results in a non-
functional IL-15 or non-functional IL-15 receptor subunit (e.g., IL 15R α, IL 15R β, or IL
15R γ).
4. IL-15
The IL-15 for use herein can be any physiologically active (i.e., functional) IL-15.
The IL-15 can be delivered as a polypeptide or a polynucleotide encoding IL-15. The IL-15
can be full-length or a physiologically active fragment thereof, for example, an IL-15
fragment that retains binding to IL-15R α and/or IL-15R β, or an IL-15 fragment that promotes
proliferation and/or maturation of T cells. In some embodiments, the delivered or expressed
IL-15 polypeptide has one or more amino acids that are substituted, added or deleted, while
still retaining the physiological activity of IL-15. In some embodiments, the delivered or
expressed IL-15 shares at least 90%, 93%, 95%, 97%, 98%, 99% or 100% amino acid
sequence identity with a wild-type IL-15, e.g., SEQ ID NO:2. In some embodiments, the
polynucleotide encoding IL-15 shares at least 90%, 93%, 95%, 97%, 98%, 99% or 100%
nucleic acid sequence identity with a wild-type IL-15 coding sequence, e.g., SEQ ID NO:1.
The polynucleotide encoding IL-15 may have one or more codons altered for
improved expression. In some embodiments, the polynucleotide encoding IL-15 shares at
least 90%, 93%, 95%, 97%, 98%, 99% or 100% nucleic acid sequence identity with a wild-
type IL-15 coding sequence, e.g., SEQ ID NO:3. In some embodiments, the polynucleotide
encoding IL-15 shares at least 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity
with a wild-type IL-15 coding sequence, e.g., SEQ ID NO:4. Polynucleotides encoding IL-
which have altered codons for improved expression are described, e.g., in WO
2007/084342 and in , the entire disclosures of each of which are hereby
incorporated herein by reference for all purposes.
The polynucleotide encoding IL-15 can be operably linked to polynucleotide
encoding a native signal peptide sequence, e.g., the long IL-15 signal peptide sequence (LSP)
or the short IL-15 signal peptide sequence (SSP). In some embodiments, the nucleic acid
sequence encoding a native IL-15 signal peptide is replaced with a nucleic acid sequence
encoding a signal peptide from a heterologous protein. The heterologous protein can be, for
example, from tissue plasminogen activator (tPA), growth hormone, granulocyte-macrophage
colony stimulating factor (GM-CSF) or an immunoglobulin (e.g., IgE). An example of a
human GMCSF-IL-15 fusion is provided in SEQ ID NO:18. In some embodiments, the
nucleic acid encoding the IL-15 is operably linked to a nucleic acid encoding an RNA export
element, for example a CTE or RTEm26CTE.
Preferably, the IL-15 is administered as a heterodimer with IL-15R α. One or both
of the IL-15 and the IL-15R α can be delivered as a polypeptide. One or both of the IL-15 and
the IL-15R α can be delivered as a polynucleotide. In one embodiment, the IL-15 and the IL-
15R α are co-administered as polypeptides. In one embodiment, an IL-15 polypeptide is co-
administered with a polynucleotide encoding IL-15R α. In one embodiment, an IL-15R α
polypeptide is co-administered with a polynucleotide encoding IL-15.
The administered IL-15R α can be any physiologically active (i.e., functional) IL-
15R α. The IL-15R α can be delivered as a polypeptide or a polynucleotide encoding IL-
15R α. The IL-15R α can be full-length or a physiologically active fragment thereof, for
example, an IL-15R α fragment that retains specific binding to IL-15. Further, the IL-15Rα,
e.g., a fragment that retains specific binding to IL-15 and lacks the transmembrane anchor
region, can be fused to an Fc region. In some embodiments, the delivered or expressed IL-
15R α polypeptide has one or more amino acids that are substituted, added or deleted, while
still retaining the physiological activity of IL-15R α. In some embodiments, the delivered or
expressed IL-15 shares at least 90%, 93%, 95%, 97%, 98%, 99% or 100% amino acid
sequence identity with a wild-type IL-15R α, e.g., SEQ ID NO:5 or SEQ ID NO:7. In some
embodiments, the polynucleotide encoding IL-15 shares at least 90%, 93%, 95%, 97%, 98%,
99% or 100% nucleic acid sequence identity with a wild-type IL-15 coding sequence, e.g.,
SEQ ID NO:6 or SEQ ID NO:8.
The polynucleotide encoding IL-15R α may have one or more codons altered for
improved expression. In some embodiments, the polynucleotide encoding IL-15R α shares at
least 90%, 93%, 95%, 97%, 98%, 99% or 100% nucleic acid sequence identity with a wild-
type IL-15Rα coding sequence, e.g., SEQ ID NO:9 or SEQ ID NO:11. Polynucleotides
encoding IL-15R α which have altered codons for improved expression are described, e.g., in
The polynucleotide encoding IL-15R α can be operably linked to polynucleotide
encoding a native signal peptide sequence. In some embodiments, the nucleic acid sequence
encoding a native IL-15R α signal peptide is replaced with a nucleic acid sequence encoding a
signal peptide from a heterologous protein. The heterologous protein can be, for example,
from tissue plasminogen activator (tPA), growth hormone, granulocyte-macrophage colony
stimulating factor (GM-CSF) or an immunoglobulin (e.g., IgE). In some embodiments, the
nucleic acid encoding the IL-15R α is operably linked to a nucleic acid encoding an RNA
export element, for example a CTE or RTEm26CTE.
In some embodiments, the IL-15Rα can be in the form of an Fc fusion protein.
Examples of sIL-15Rα polypeptide sequences are shown in SEQ ID NO:17 and SEQ ID
NO:20. Typically, such proteins are secreted and can be found soluble in the plasma, or they
can be associated with the surface of cells expressing the Fc receptor for the Fc region of the
fusion protein. Different fragments of IL-15Rα can be fused to the Fc region. Two examples
of functional fusions are provided as SEQ ID NO:17 and SEQ ID NO:20, containing 205 or
200 amino acids within the IL-15Rα region. In some embodiments, the IL-15Rα region of
the fusion protein can be released by proteolytic cleavage. In some embodiments, I-L15Rα
functional region of the protein is linked to a polypeptide that is able to bind specific cell
types via surface receptors. In some embodiments, the IL15-Rα Fc fusion protein shares at
least 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with a polypeptide
selected from the group consisting of SEQ ID NO:17 and SEQ ID NO:20.
In some embodiments, a polynucleotide encoding IL-15 is co-administered with a
polynucleotide encoding IL-15R α. The polynucleotide encoding IL-15 and the
polynucleotide encoding IL-15R α can be administered on the same vector or on separate
vectors. Preferably the polynucleotide encoding IL-15 is co-administered with a
polynucleotide encoding IL-15R α are on the same vector. An example of a plasmid that
encodes an IL-15Rα-Fc fusion having a polypeptide sequence of SEQ ID NO:17 and a
human GM-CSF signal peptide-IL-15 of SEQ ID NO:18 is provided in SEQ ID NO:16. A
second example of a plasmid that encodes an IL-15Rα-Fc fusion having a polypeptide
sequence of SEQ ID NO:20 and a human GM-CSF signal peptide-IL-15 of SEQ ID NO:18 is
provided in SEQ ID NO:19.In some embodiments, the administered vector shares at least
95%, 97%, 98%, 99% or 100% nucleic acid sequence identity with a plasmid vector selected
from the group consisting of SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID
NO:16, and SEQ ID NO:19.
It is understood by one skilled in the art that expression vectors, promoters,
polyadenylation signals, and secretory peptides alternatives to those in the example
sequences provided herein can be used for the expression of the optimized IL-15 and IL-15
Receptor alpha.
For the purposes of the present methods, the IL-15 is not being used as an adjuvant
to enhance the immune response against a particular antigen. Therefore, in the present
methods, the IL-15 is administered without an antigen. Stated another way, the IL-15 is not
co-administered with an antigen.
The IL-15 (and the IL-15R α) are administered at a dose sufficient to achieve
supraphysiological levels of IL-15 systemically or in the target tissue, e.g., thymus, for the
desired time period. The desired time period can be hours, days, weeks, or longer if
necessary. In some embodiments, supraphysiological levels of IL-15 are sustained
throughout the duration of treatment or until a desired therapeutic endpoint is achieved, e.g.,
the repopulation of peripheral tissues with lymphocytes. In some embodiments, the IL-15 is
administered one time, as a bolus. In some embodiments, the IL-15 is administered two or
more times. When administered multiple times, the IL-15 can be administered daily, weekly,
bi-weekly, monthly, or as needed to sustain supraphysiological levels of IL-15 systemically
or in the target tissue.
In embodiments where the IL-15 (and the IL-15R α) are administered as a
polypeptide, typical dosages can range from about 0.1 mg/kg body weight up to and
including about 0.5 mg/kg body weight. In some embodiments, the dose of polypeptide is
about 0.01, 0.02, 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5 mg/kg body weight.
In embodiments where the IL-15 (and the IL-15R α) are administered as a
polynucleotide, dosages are sufficient to achieve plasma levels of IL-15 of about 1 to 1000
ng/ml, for example, plasma levels of IL-15 of about 10 to 1000 ng/ml. Such a range of
plasma concentrations can be achieved, e.g., after intramuscular electroporation of about 0.1
mg IL-15/IL-15sR α expressing DNA plasmid per kg body weight.. In some embodiments,
the dose of nucleic acid is about 0.02, 0.05, 0.1, 0.2, 0.5 mg/kg body weight.
The IL-15 can be administered by a route appropriate to effect systemic
supraphysiological levels of IL-15 or supraphysiological levels of IL-15 in the target tissue,
e.g., thymus. When co-administered with IL-15R α, the IL-15 and the IL-15R α can be
administered via the same or different routes. In some embodiments, the IL-15 (and the IL-
15R α) are administered systemically, including without limitation, enterally (i.e., orally) or
parenterally, e.g., intravenously, intramuscularly, subcutaneously, intradermally, intranasally,
or inhalationally. In some embodiments, the IL-15 (and the IL-15R α) are administered
locally, for example, intrathymically or directly into the bone marrow.
For treatment of lymphopenia, systemic administration of IL-15 promotes and
accelerates the repopulation of peripheral lymphocyte populations. After administration of
IL-15, the peripherally circulating lymphocytes or lymphocyte subpopulations can be at least
80%, 85%, 90% or 95% of levels considered to be normal in a healthy individual. In some
embodiments, the lymphocytes or lymphocyte subpopulations are completely repopulated to
normal levels. In some embodiments, the repopulation of lymphocytes is days or weeks
faster in an individual who received administration of IL-15 in comparison to an individual
who did not receive administration of IL-15.
Systemic administration of IL-15 also prevents, reduces or inhibits lymphocyte
depletion in peripheral circulation, e.g., caused by chemotherapy or radiation therapy. After
administration of IL-15, the peripherally circulating lymphocytes or lymphocyte
subpopulations can be maintained at levels of at least 70%, 75%, 80%, 85%, 90% or 95% of
normal levels. In some embodiments, the lymphocytes or lymphocyte subpopulations are
maintained at normal levels.
In some embodiments, the IL-15 is co-administered with a chemotherapeutic agent
that causes or may cause lymphopenia or lymphocyte depletion in peripheral tissues. The
chemotherapeutic agent may be an anticancer agent or an antiviral agent. In some
embodiments, the IL-15 is administered after a course of treatment with a chemotherapeutic
agent that causes or may cause lymphopenia or lymphocyte depletion in peripheral tissues.
In some embodiments, the IL-15 is administered prior to, during or after a course of radiation
therapy.
EXAMPLES
The following examples are offered to illustrate, but not to limit the claimed
invention.
Example 1: Systemic Administration of IL-15 Promotes Maturation of T cells in the Thymus
and the Migration of T cells to Peripheral Tissues
IL-15/IL-15R α DNA was expressed systemically and locally at various levels in
either normal or IL-15 knockout (KO) mice to further understand IL-15 biology. See,
Bergamaschi, et al., (2008) J Biol Chem 283:4189-4199. Supraphysiologic levels of IL-
/IL-15R α in normal mice have rapid and profound effects in many tissues. There is a rapid
and reversible increase in the size of spleen, whereas the thymus becomes smaller and bone
marrow lymphocyte numbers decrease (Figure 2). We have previously shown that spleen
and lymph node size increase is proportional to the amount of IL-15 in the plasma. See,
Bergamaschi, et al., (2008) J Biol Chem 283:4189-4199. The kinetics and composition of
lymphocytes in many tissues were studied using 10 parameter flow cytometry, as well as
adoptive transfer of cells and in vivo labeling. Our results underscore the strong effects of IL-
at all steps of lymphocyte development, as also suggested by many investigators.
Reviewed in, e.g., Boyman, et al., (2007) Curr Opin Immunol 19:320-326: Sprent, et al.,
(2008) Immunol Cell Biol 86:312-319; Sprent and Surh, (2003) Immunol Lett 85:145-149;
Surh, et al., (2006) Immunol Rev 211:154-163; Surh and Sprent, (2005) Semin Immunol
17:183-191; and Surh and Sprent, (2008) Immunity 29:848-862. However, prior to the
present invention, the effects of IL-15 in the thymus have not been elucidated. Our results
indicate that IL-15 stimulates the maturation of CD4+CD8+ double positive thymocytes into
CD3high single positive T cells (Figure 3) and accelerates their rapid migration to the
periphery (Figure 4). Seven days after in situ labeling of thymocytes, IL-15/IL-15R α
promoted their migration to the lung. In the presence of IL-15/IL-15R α the lymphocytes in
the lung have higher levels of IL-2/IL-15R α (CD122, see, Figure 4, bottom) indicating that
they are activated. These results are consistent with the notion that IL-15 promotes not only
accelerated exit from the thymus, but also the migration to peripheral tissues and the
activation of these lymphocytes.
Our results also show that, in addition to NK and memory CD8+ T cells that are
profoundly affected, as expected, all lymphocytes including naïve and memory CD4 and
CD8 cells, and B lymphocytes are also affected to either divide, migrate or be activated. This
is in agreement with the widespread (but not universal) expression of the IL-2/IL-15
betagamma receptor. The hierarchy of responsiveness of the lymphocyte subsets to IL-15
reflects the levels of CD122 (IL-2Rbeta) on their surface. See, Bergamaschi, et al., (2008) J
Biol Chem 283:4189-4199.
Our observations are further supported by experiments performed in an IL-15 KO
model, to correct the lymphocyte defects by administering plasmid DNA encoding
IL-15/IL-15R α heterodimer. IL-15 KO mice are characterized by a decrease in total T cell
count that preferentially affects CD8+ T cells, which are almost completely absent in
peripheral tissues. We show that IL-15/IL-15R α is able to repopulate non-lymphoid organs,
such as lungs, with both mature CD4 and CD8 T lymphocytes. The increase in CD4 T cells
upon IL-15/IL-15R α treatment is 10-fold, while the increase in the CD8+ population is
significantly greater, reaching 100-fold (Figure 5). These results underscore the feasibility of
using IL-15/IL-15R α DNA to correct defects associated with lymphopenia (e.g., caused by
total absence of IL-15 or of another etiology). Analysis of lymphocytes migrating in
different organs in the presence of IL-15 suggests that many acquire rapidly a memory
phenotype in the absence of antigen recognition and that IL-15 promotes re-entry of some
lymphocytes into the thymus. The issue of lymphocyte re-entry in the thymus is
controversial, and the study of IL-15 effects may contribute to the understanding of this
phenomenon. See, Sprent and Surh (2009) Immunol Cell Biol 87:46-49; Bosco, et al., (2009)
Immunol Cell Biol 87:50-57; Agus, et al., (1991) J Exp Med 173:1039-1046. Our
preliminary data indicate that transfer of CFSE loaded thymocytes into normal mice results in
homing into the thymus only in animals receiving IL-15.
We have found that IL-15 decreases the frequency of apoptotic thymocytes, mainly
by promoting their terminal differentiation into mature single positive T cells. Our results
after intrathymic injection of CFSE indicate that IL-15 increases thymic output, as reflected
by the higher frequency of fully mature CFSE labeled T cells in the spleen and lung of IL-15
treated mice.
We have further observed that the enlarged spleen size upon IL-15 treatment is
partially due to increased frequency of B lymphocytes, either by local proliferation, B cell
migration from other compartments, or both. In addition, during in vivo experiments with
adoptive transferred CFSE-labeled splenocytes we observed ILinduced proliferation of
both CD4 naïve and memory T cells. In contrast to CD8+ T cells, which almost universally
proliferate in the presence of IL-15, the CD4+ T cell responses appear to be restricted to a
subset of cells.
Example 2: Correction of Cyclophosphamide-Induced Lymphopenia by IL-15/IL-15R α
DNA Administration
Summary
The present example shows the reversal of cyclophosphamide-induced lymphopenia
in normal young mice by systemic administration of IL-15. One or two high doses of IL-15
were administered two (2) days (or two (2) and twelve (12) days) after cyclophosphamide by
hydrodynamic DNA injection. The results show that mice recover faster from lymphopenia
after IL-15 administration in comparison to control mice with cyclophosphamide-induced
lymphopenia that did not receive IL-15. Lymphocytes recovered faster in peripheral tissues
after IL-15 administration. NK cells were the first to recover, whereas T cells recovered in
approximately one month. In the course of these studies, we discovered that two
administrations of IL-15 improved T cell recovery over a single administration of IL-15. In
addition, low and sustained levels of IL-15 provides for a more efficient repopulation of
lymphocytes to the peripheral tissues in comparison to a single high dose. These results
demonstrate that IL-15 is useful in treating and/or preventing lymphopenia.
Methods
Cyclophosphamide administration
Six-to-eight week old female Balb/c mice were obtained from Charles River
Laboratory (Frederick, MD). Cyclophosphamide (Sigma) was dissolved in pyrogen-free
saline and injected intra-peritoneally (i.p.) at a dose of 200 mg/kg of body weight. Two
treatments with cyclophosphamide were performed at day -4 and -2.
DNA Injection
On day 0, hydrodynamic injection of either a control vector or IL-15 and IL-15R α
expression plasmid into cyclophopshamide treated mice was performed. Empty vector DNA
was also administered to the cyclophopshamide-untreated mice, as control. Briefly, 0.2 µg to
2 µg of DNA in 1.6 ml of sterile 0.9% NaCl were injected into mice through the tail vein
within 7 seconds using a 27.5 gauge needle. Highly purified, endotoxin-free DNA plasmids
were produced using Qiagen EndoFree Giga kit (Qiagen, Hilden).
Lymphocyte analysis
Mice were sacrificed at different time points (days 2-26) after DNA injection and
serum, bone marrow, thymus, spleen, liver and lungs were collected for analysis.
For bone marrow lymphocyte isolation, left and right femurs were collected and
centrifuged at 13,000 for 5 min, re-suspended, and centrifuged again (total of 3 times).
Collected cells were re-suspended in RPMI containing 10% fetal calf serum and viable cells
were counted using Acridine Orange (Molecular Probes)/Ethidium Bromide (Fisher) dye.
For splenocyte or thymocyte isolation, spleens or thymi were gently squeezed
through a 100 µm Cell Strainer (Thomas) and washed in RPMI (Gibco) to remove any
remaining lymphocytes from the organ stroma. After centrifugation, the cells were re-
suspended in RPMI containing 10% fetal calf serum and counted.
To isolate lymphocytes from livers or lungs, the tissues were minced and incubated
with 200 U/ml of collagenase (Sigma) and 30 U/ml of DNase (Roche) for 1 h at 37°C, then
single cells were collected, centrifuged and re-suspended in complete RPMI with 10% fetal
calf serum.
For phenotyping, the cells were incubated with the following mix of directly
conjugated anti-mouse antibodies (BD Pharmingen): CD3-APC, CD4-PerCP, CD8-PECy7,
CD44-APC, CD49b-FITC, CD19-PE, CD62L-PE. Labeled cell samples were analyzed by
flow cytometry using an LSR II Flow Cytometer (BD) and were analyzed using FlowJo
software (Tree Star, San Carlos, CA).
Lymphocytes of the different group of mice were counted and compared. Statistical
analyses were performed using the Prism Software Program. Comparisons of two groups
were performed by non-parametric Mann-Whitney t test. Confidence intervals were 0.05, and
all p values were two-tailed.
Results
Two injections of cyclophosphamide at days -4 and -2 were used to generate
lymphodepleted mice. At day 0 (and also, for some mice at day 10) IL-15/15R α DNA
expression vector was injected in the tail vein, which generated high systemic levels of
bioactive IL-15/15R α, as published (Bergamaschi, et al., J Biol Chem. (2008) 283(7):4189-
99). The biological effects after injection of IL-15/15R α DNA were compared to the
injection of a non-producing DNA (vector BV) as negative control in cyclophosphamide-
treated animals.
Different tissues, including lung, liver, spleen, thymus and bone marrow, were
extracted from mice sacrificed at days 2-26 from DNA injection and the lymphocyte
populations were studied.
Cyclophosphamide treatment had strong effects on lymphocytes, as reflected in the
increased spleen weight of treated animals (Figure 7). Four animals per time point were
sacrificed and the spleen weight was monitored. The two groups treated with
cyclophosphamide (CP+vector, treated with a non-producing DNA vector; CP+IL-15) had a
smaller spleen at day 2 after DNA treatment (4 days after cyclophosphamide). At this early
point and also at day 5 the IL-15 treated animals showed a statistically significant difference
in spleen size, indicating accelerated recovery by IL-15.
Lung
We also analyzed lymphocyte numbers and subsets in different tissues to evaluate
the effects of IL-15/15R α administration. These experiments were performed after one or
two IL-15/15R α DNA administrations (at days 0 and 10).
Lung lymphocytes were evaluated in order to determine the effects of IL-15/15R α
on a peripheral site, where lymphocytes need to function. IL-15 is known to affect strongly
CD8+ T cells and NK cells. High levels of IL-15 (achieved with two injections of 2 µg DNA
at days 0 and 10), favors lymphocyte recovery in the lung after Cyp treatment.
Effects on Natural Killer (NK) cells:
Mice were treated at days -4 and -2 and injected with DNA at day 0. Two groups of
mice were injected with either BV negative control DNA or with IL-15/IL-15R α DNA. The
IL-15/IL-15R α-treated animals had a trend for higher NK numbers for all time points. At day
14, comparison of the group receiving empty vector with the group of 2x IL-15/IL-15R α
administration (DNA injections at days 0 and 10) showed that IL-15/15R α significantly
increased lung NK cell recovery (p=0.03).
The lymphocyte population that recovers first is the NK cells. In our experiments
after cyclophosphamide treatment the NK cells recovered partially in the absence of any
other intervention. IL-15/15R α administration accelerated this recovery. The best recovery
was observed after two IL-15 injections at days 0 and 10. Examination at day 14 showed a
significant increase in NK by IL-15 compared to Cyp (p=0.03). See, Figure 8.
Effects on Lung T cells
In contrast to NK cells, lung T cells do not recover as fast. The mice were treated
and analyzed as above. Lung T cells were enumerated at day 14 after the first DNA
injection. It was found that total T cells increased at day 14 after two IL-15/R α
administrations at days 0 and 10, compared to the Cyp treated animals. See, Figure 9.
The lung T cells were also distinguished according to expression of CD4 or CD8
and compared among different groups of mice. It was found that the CD8+ T cells increased
preferentially after IL-15/15R α administration at day 14 (p=0.0357). Moreover, at days 6
and 14 the CD8/CD4 ratio was increased, demonstrating the preferential stimulation of CD8+
T cells by IL-15. The ratio returns to normal by day 26, in the group that received IL-
/15R α. See, Figures 10 and 11.
Spleen
In the spleen, we also found that T cells recover faster after two injections of
IL-15/15R α (p= 0.0357). Similar to the results in the lung, two doses of IL-15/15R α (days 0
and 10) were able to increase spleen lymphocytes after Cyp (p=0.03). See, Figure 12.
Bone Marrow
Sustained high level of IL-15 (achieved with two injections of 2 µg DNA at days 0
and 10) resulted in T cell recovery in bone marrow by day 14 after the first DNA injection
(Figure 13). IL-15 affected both CD4 and CD8 compartments. Treatment with two
administrations of IL-15/15R α resulted in high levels of bone marrow T cells at day 14
compared to Cyp treated animals.
Example 3: Therapeutic effects of IL-15 on lymphopenia in two different mouse strains
This example also employed Black6 mice to analyze therapeutic effects of various
forms of IL-15 on lymphopenia. Two different mouse strains, BALB/c and Black6, were
used in these experiments. Both strains showed accelerated lymphocyte reconstitution upon
treatment with IL-15/IL-15Rα.
Treatment of lymphoablated mice with IL-15 DNA
Female Balb/c or Black6 mice 6-8 weeks in age were treated intra-peritoneally with
a dose of 200 mg/kg of body weight of cyclophosphamide (CYP, Figure 14). Two injections
of CYP were performed at day -4 and day -2. At day 0 and day 5, hydrodynamic injection of
either a control DNA or DNA expressing IL-15/IL-15sRα soluble molecule was performed.
Control vector was also delivered in CYP-untreated mice as control. Mice were sacrificed at
different time points: day -1 to assess the CYP-induced lymphoablation and day 5, 10, 17 and
24 to follow immune reconstitution in presence or absence of exogenous IL-15. Different
tissues (spleen, thymus, bone marrow, lung and liver) were harvested and analyzed for the
presence of different lymphocyte subsets. Analysis was performed by flow cytometry after
staining the cells with fluorescent-labeled antibodies.
For flow analysis, isolated cells were incubated with the following directly
conjugated anti-mouse antibodies (BD Pharmingen) in appropriate combinations according to
the objectives of the experiment:
CD3-APC or CD3-APC-Cy7, CD4-PerCp, CD8-Pacific Blue, CD44-APC, CD62L-PE,
CD19-APC-Cy7 or CD19-PeCy7, CD49b-FITC, CD25-APC-Cy7, CD122-PE. T cells were
+ - +
defined as CD3 cells in the lymphocyte gate; NK cells were defined as CD3 CD49b cells.
+ + +
For identification of Treg population (T CD4 CD25 FoxP3 cells), the cells were
fixed and permeabilized (eBioscience), and incubated with anti-mouse FoxP3-PeCy7
antibody (eBioscience). T effector cells were defined as CD3 FoxP3 lymphocytes.
Therefore, the term “Teffector” as used in here refers to all T cells except Treg.
Figure 15 shows the reconstitution of NK cell compartment in spleen and lung after
CYP treatment. CYP-untreated mice were used as baseline control (squares). Two injections
of CYP resulted in a drastic reduction of the absolute number of NK cells in both spleen and
lung (day -1). NK cells spontaneously recover between day 10 and day 14 days after control
DNA injection (triangles). One single administration of IL-15/IL-15sRα DNA was able to
promote a full recovery of NK within 5 days after DNA injection. The second IL-15/IL-
15sRα expressing DNA injection resulted in an even further expansion of NK cells in both
spleen and lung (circles).
Figure 16 shows the reconstitution of T cell compartment in spleen and lung after
CYP treatment. CYP-untreated mice were used as baseline control (squares). Two injections
of CYP resulted in a 4 fold reduction in the level of splenic T cells and in 10 fold reduction in
the level of T cells residing in the lung (day -1). The spontaneous recovery of T cells
appeared to be slower in comparison with the recovery of NK cells and was still incomplete
at day 24 after control DNA injection. The kinetics of spontaneous recovery of T CD8 and T
CD4 was similar in both spleen and lung (triangles). Two injections of DNA expressing IL-
/IL-15sRα were able to fully reconstitute the T cell numbers within 10 days after DNA
administration in both spleen and lung. IL-15 promoted mainly the expansion of T CD8 cells
that reached normal level at day 5 after DNA injection and were boosted over normal level at
day 10 after DNA injection. IL-15 did not significantly affect the recovery of T CD4 and B
cells.
In addition, T cells recovering in the presence of high level of IL-15/IL-15sRα
show increased T effector (Teff)/T regulatory (Treg) ratio and increased ability to secrete
IFNgamma and greater degranulation after in vitro stimulation. Figure 17 is an analysis of
the Teff/Treg ratio after CYP treatment for lymphodepletion and during the recovery phase.
The Teff/Treg ratio increased significantly at day 10 after IL-15/15sRα DNA injection.
Example 4. DNA delivery for IL-15 to treat lymphopenia
In these examples, three preferred DNA vector combinations are evaluated for the
therapeutic delivery of IL-15 to treat lymphopenia:
1 Co-delivery in the same cells, using preferably optimized expression plasmids
expressing IL-15 and essentially full-length IL-15R α, such as SEQ ID NO:13 and SEQ ID
NO:14.
2 Co-delivery in the same cells, using preferably optimized expression plasmids
expressing IL-15 and soluble (s) IL-15R α, such as SEQ ID NO:15.
3 Co-delivery in the same cells, using preferably optimized expression plasmids
expressing IL-15 and IL-15R α fusions to the constant region of an immunoglobulin molecule
(Fc) such as SEQ ID NO:16 and SEQ ID NO:19. The construction of Fc fusion proteins is
known in the art. Such constructs have been used in in vivo experiments in mice to show that
IL-15 and IL15R α-Fc fusion heterodimers are active in vivo.
Delivery of IL-15/IL-15Rα heterodimer by approach (1) above leads to expression
of both plasma membrane-bound and secreted IL-15/IL-15Rα. Delivery by approach (2)
leads to exclusively secreted IL-15/IL-15Rα heterodimer. Delivery by approach (3) leads to
a secreted bioactive heterodimer, which is then bound to cells expressing the Fc Ab receptor
on their surface. These cells can present the IL-15/IL-15RαFc heterodimer to neighboring
cells, resulting in activation.
The three types of vectors have been tested in mice and have been shown to produce
systemically bioactive levels of IL-15/IL-15Rα (see Figure 18, showing expression of the
three types of complexes). Because the localization, trafficking and stability of the different
types of complexes vary, the biological effects on lymphocytes is also variable. Figure 18
shows expression of different IL-15/IL-15Rα heterodimeric forms in mice by hydrodynamic
injection of DNA vectors. Mice were injected at the tail vein (hydrodynamic delivery) with
0.1 µg of DNA expressing the different forms of IL-15/IL-15Rα. Plasma levels of IL-15
were measured at days 1 and 2.5 by R&D Quantiglo ELISA. Measurement of plasma levels
of IL-15 produced by the different vectors showed that the highest plasma levels were
achieved by the DNA vector producing IL-15/IL-15RαFc fusion. The stability of the
produced proteins was also different, with the IL-15/IL-15RαFc and the IL-15/IL-15Rα full
length showing the greatest stability. The IL-15/sIL-15Rα that is not cell associated was less
stable.
Table 2 shows the CD4/CD8 ratios measured in the spleen and lung of mice treated
with different IL-15/IL-15Rα heterodimeric forms, 2 ½ days after hydrodynamic injection of
0.1 µg of DNA vector (see Figure 17).
VECTOR Spleen Lung
1.36 0.8
IL-15/IL-15Rα (full length)
0.81 0.24
IL-15/sIL-15Rα (soluble)
0.63 0.52
IL-15/IL-15RαFc fusion to Fc
DNA vector control 2 1.61
In these experiments, it was discovered that the different molecules have differential
effects on lymphocytes. Therefore, the different IL-15 complexes can be used alone or in
combinations for the most beneficial treatment under specific conditions. For example,
delivery of combinations of IL-15/sRα soluble complex and IL-15/15RαFc fusion complex
provides the opportunity to deliver both soluble and cell-bound IL-15 (through the Fc
receptor) at different levels and proportions.
In addition to the different ratios of CD4/CD8 cells (as shown in Table 1), the
different IL-15 heterodimers also showed differences in the effects on other surface markers
of lymphocytes. Figure 19 shows that IL-15/15RαFc expression induced high levels of
CD25 (IL-2 Receptor alpha) on both T CD4 and T CD8 cells, whereas the other forms of IL-
/IL-15Rα heterodimers did not affect CD25 expression strongly.
Figure 20 shows that IL-15/IL-15RαFc increased the levels of CD62L on the
surface of spleen T cells, whereas the other forms of IL-15/IL-15Rα either did not affect or
decreased average levels of CD62L on spleen T cells. In contrast, IL-15/IL-15RαFc was less
effective in increasing CD44 on spleen T cells compared to either IL-15/IL-15Rα full-length
or IL-15/IL-15sRα (Figure 21).
Example 5. Protein Delivery
As an alternative method to provide IL-15, delivery of purified protein can be used.
Protein purification from cell lines over-producing IL-15/IL-15Rα complexes has been
achieved. Similar to DNA, different forms of the heterodimer can be used alone or in
combinations for obtaining the appropriate effects:
1 Delivery of purified IL-15/soluble (s) IL-15R α, such as SEQ ID NO:10 and SEQ ID
NO:12.
2 Delivery of purified IL-15/IL-15R αFc fusion protein (fusion to the constant region
of an immunoglobulin molecule, such as SEQ ID NO:17 and SEQ ID NO:20)
IL-15/sIL-15Rα was purified from overproducing human 293 cells and delivered
into lympho-ablated mice. The results showed that this heterodimer is bioactive and that it
promoted the proliferation of adoptively transferred lymphocytes (T cells, NK cells, but not
B cells).
Experimental procedure (Figure 22): Mice were treated with Cyclophosphamide
(Cyp) and two days later they were given 3 µg of HPLC-purified IL-15/s15Ra protein
intraperitoneally for 6 days. Splenocytes were purified from young Bl/6 mice, labeled with
CFSE, and 10 cells were injected by the IV route to the lympho-ablated animals.
Proliferation of the adoptively transferred cells was followed by CFSE dilution.
Thus, these results indicate that different forms of IL-15/IL-15Rα heterodimer have
different stability, interactions in the body, processing and stability. This offers the
opportunity to exploit such properties for using these cytokines to provide maximal benefit.
Accordingly, the different forms can be combined in different ratios and administration
schedules. Different forms can be administered either simultaneously or sequentially.
IL-15Rα – Fc fusions previously employed have been used with various degrees of
effectiveness. The studies exemplified in Figure23 show that the Fc fusion we used has
greater plasma half-life compared to IL-15/s15Rα.
In the examples of sequences, described herein, the 205FC fusion (SEQ ID NO:17)
contains the natural processing site generating the s15Rα from the membrane-bound form,
whereas the 200FC fusion (SEQ ID NO:20) does not have an intact processing site. These
are examples of Fc fusions that may be processed differently to generate non-cell associated
forms after cleavage between the 15Rα region and the antibody constant region. Additional
molecules can be generated having processing sites for cleavage and generating both cell
associated and soluble forms of the cytokine. Additional methods for cell attachment, other
than the Fc region are known in the art and can also be employed.
It is understood that the examples and embodiments described herein are for
illustrative purposes only and that various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included within the spirit and purview of
this application and scope of the appended claims. All publications, patents, and patent
applications cited herein are hereby incorporated by reference in their entirety for all
purposes.
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission that
such documents, or such sources of information, in any jurisdiction, are prior art, or form part
of the common general knowledge in the art.
In the description in this specification reference may be made to subject matter that is
not within the scope of the claims of the current application. That subject matter should be
readily identifiable by a person skilled in the art and may assist in putting into practice the
invention as defined in the claims of this application.
The following numbered paragraphs define particular aspects of the present invention:
1. A method of promoting T-cell maturation in thymic tissue comprising
contacting the thymic tissue with IL-15.
2. The method of paragraph 1, wherein the thymic tissue is in vivo.
3. The method of paragraph 2, wherein the IL-15 is administered
systemically.
4. The method of paragraph 2, wherein the IL-15 is administered locally.
. The method of paragraph 1, wherein the thymic tissue is in vitro.
6. The method of paragraph 1, wherein the IL-15 is delivered as a
heterodimer with IL-15R α.
7. The method of paragraph 6, wherein the IL-15Rα is a soluble IL
Rα that lacks the transmembrane anchor portion and is fused to an Fc region.
8. The method of paragraph 1, wherein the IL-15 is delivered as a
polypeptide.
9. The method of paragraph 1, wherein the IL-15 is expressed from a
polynucleotide encoding IL-15.
. The method of paragraph 9, wherein the IL-15 is co-expressed from a
single vector with a polynucleotide encoding IL-15R α.
11. The method of paragraph 9, wherein the IL-15 is co-expressed from
separate vectors with a polynucleotide encoding IL-15R α.
12. The method of paragraph 1, wherein the IL-15 has a native signal
peptide.
13. The method of paragraph 1, wherein the IL-15 has a heterologous
signal peptide.
14. A method of promoting the migration of lymphocytes from a central
lymphoid tissue to one or more peripheral tissues in a subject in need thereof comprising
administering to the subject IL-15.
. The method of paragraph 14, wherein the central lymphoid tissue is
thymus.
16. The method of paragraph 14, wherein the lymphocytes are T cells.
17. The method of paragraph 14, wherein the peripheral tissue is a
peripheral lymphoid tissue.
18. The method of paragraph 14, wherein the peripheral tissue is a non-
lymphoid tissue.
19. The method of paragraph 14, wherein the IL-15 is administered
systemically.
. The method of paragraph 14, wherein the IL-15 is administered
locally.
21. The method of paragraph 14, wherein the IL-15 is delivered as a
heterodimer with IL-15R α.
22. The method of paragraph 14, wherein the IL-15Rα is a soluble IL
Rα that lacks the transmembrane anchor portion and is fused to an Fc region.
23. The method of paragraph 14, wherein the IL-15 is delivered as a
polypeptide.
24. The method of paragraph 14, wherein the IL-15 is expressed from a
polynucleotide encoding IL-15.
. The method of paragraph 24, wherein the IL-15 is co-expressed from a
single vector with a polynucleotide encoding IL-15R α.
26. The method of paragraph 24, wherein the IL-15 is co-expressed from
separate vectors with a polynucleotide encoding IL-15R α.
27. The method of paragraph 14, wherein the IL-15 has a native signal
peptide.
28. The method of paragraph 14, wherein the IL-15 has a heterologous
signal peptide.
29. A method of preventing or reducing lymphopenia in an individual in
need thereof comprising systemically administering IL-15 to the individual.
. The method of paragraph 29, wherein the IL-15 is delivered as a
heterodimer with IL-15R α.
31. The method of paragraph 30, wherein the IL-15Rα is a soluble IL
Rα that lacks the transmembrane anchor portion and is fused to an Fc region.
32. The method of paragraph 29, wherein the IL-15 is delivered as a
polypeptide.
33. The method of paragraph 29, wherein the IL-15 is expressed from a
polynucleotide encoding IL-15.
34. The method of paragraph 33, wherein the IL-15 is co-expressed from a
single vector with a polynucleotide encoding IL-15R α.
. The method of paragraph 33, wherein the IL-15 is co-expressed from
separate vectors with a polynucleotide encoding IL-15R α.
36. The method of paragraph 29, wherein the IL-15 has a native signal
peptide.
37. The method of paragraph 29, wherein the IL-15 has a heterologous
signal peptide.
38. The method of paragraph 29, wherein the lymphopenia is drug-induced
lymphopenia.
39. The method of paragraph 29, wherein the individual is receiving
anticancer drugs that induce lymphopenia.
40. The method of paragraph 39, wherein the IL-15 is co-administered
with the anticancer agent.
41. A method of promoting the repopulation of lymphocytes in peripheral
tissues in an individual in need thereof comprising systemically administering IL-15 to the
individual.
42. The method of paragraph 41, wherein the IL-15 is delivered as a
heterodimer with IL-15R α.
43. The method of paragraph 41, wherein the IL-15 is delivered as a
polypeptide.
44. The method of paragraph 41, wherein the IL-15 is expressed from a
polynucleotide encoding IL-15.
45. The method of paragraph 44, wherein the IL-15 is co-expressed from a
single vector with a polynucleotide encoding IL-15R α.
46. The method of paragraph 44, wherein the IL-15 is co-expressed from
separate vectors with a polynucleotide encoding IL-15R α.
47. The method of paragraph 41, wherein the IL-15 has a native signal
peptide.
48. The method of paragraph 41, wherein the IL-15 has a heterologous
signal peptide.
49. The method of paragraph 41, wherein the peripheral tissue is a
peripheral lymphoid tissue.
50. The method of paragraph 41, wherein the peripheral tissue is a non-
lymphoid tissue.
EXAMPLES OF SEQUENCES
SEQ ID NO:1
Human wild-type IL-15 nucleic acid sequence
ATGAGAATTTCGAAACCACATTTGAGAAGTATTTCCATCCAGTGCTACTTGTGTTTACTTCT
AAACAGTCATTTTCTAACTGAAGCTGGCATTCATGTCTTCATTTTGGGCTGTTTCAGTGCAG
GGCTTCCTAAAACAGAAGCCAACTGGGTGAATGTAATAAGTGATTTGAAAAAAATTGAAGAT
CTTATTCAATCTATGCATATTGATGCTACTTTATATACGGAAAGTGATGTTCACCCCAGTTG
CAAAGTAACAGCAATGAAGTGCTTTCTCTTGGAGTTACAAGTTATTTCACTTGAGTCTGGAG
ATGCAAGTATTCATGATACAGTAGAAAATCTGATCATCCTAGCAAACAACAGTTTGTCTTCT
AATGGGAATGTAACAGAATCTGGATGCAAAGAATGTGAGGAACTGGAGGAAAAAAATATTAA
AGAATTTTTGCAGAGTTTTGTACATATTGTCCAAATGTTCATCAACACTTCTTGA
SEQ ID NO:2
Human wild-type IL-15 amino acid sequence
M R I S K P H L R S I S I Q C Y L C L L L
N S H F L T E A G I H V F I L G C F S A G
L P K T E A N W V N V I S D L K K I E D L
I Q S M H I D A T L Y T E S D V H P S C K
V T A M K C F L L E L Q V I S L E S G D A
S I H D T V E N L I I L A N N S L S S N G
N V T E S G C K E C E E L E E K N I K E F
L Q S F V H I V Q M F I N T S •
SEQ ID NO:3
Human improved IL-15 nucleic acid sequence (opt1)
ATGCGGATCTCGAAGCCGCACCTGCGGTCGATATCGATCCAGTGCTACCTGTGCCTGCTCCT
GAACTCGCACTTCCTCACGGAGGCCGGTATACACGTCTTCATCCTGGGCTGCTTCTCGGCGG
GGCTGCCGAAGACGGAGGCGAACTGGGTGAACGTGATCTCGGACCTGAAGAAGATCGAGGAC
CTCATCCAGTCGATGCACATCGACGCGACGCTGTACACGGAGTCGGACGTCCACCCGTCGTG
CAAGGTCACGGCGATGAAGTGCTTCCTCCTGGAGCTCCAAGTCATCTCGCTCGAGTCGGGGG
ACGCGTCGATCCACGACACGGTGGAGAACCTGATCATCCTGGCGAACAACTCGCTGTCGTCG
AACGGGAACGTCACGGAGTCGGGCTGCAAGGAGTGCGAGGAGCTGGAGGAGAAGAACATCAA
GGAGTTCCTGCAGTCGTTCGTGCACATCGTCCAGATGTTCATCAACACGTCGTGA
SEQ ID NO:4
Human improved IL-15 nucleic acid sequence (opt2)
ATGAGGATCAGCAAGCCCCACCTGAGGAGCATCAGCATCCAGTGCTACCTGTGCCTGCTGCT
GAACAGCCACTTCCTGACCGAGGCCGGTATACACGTGTTCATCCTGGGCTGCTTTAGCGCCG
GACTGCCCAAGACCGAGGCCAATTGGGTGAACGTGATCAGCGACCTGAAGAAGATCGAGGAC
CTCATCCAGAGCATGCACATCGACGCCACCCTGTACACCGAGAGCGATGTGCACCCCAGCTG
TAAGGTGACCGCCATGAAGTGCTTTCTGCTGGAGCTGCAAGTGATCAGCCTGGAGAGCGGCG
ACGCCAGCATCCACGACACCGTGGAGAACCTGATCATCCTGGCCAACAACAGCCTGAGCAGC
AACGGCAATGTGACCGAGAGCGGCTGTAAGGAGTGTGAGGAGCTGGAGGAGAAGAACATCAA
GGAGTTTCTGCAGAGCTTCGTGCACATCGTGCAGATGTTCATCAACACCAGCTGA
SEQ ID NO:5
Homo sapiens interleukin 15 receptor, alpha (IL15RA),
transcript variant 1, mRNA – GenBank Accession No. NM_002189
1 cccagagcag cgctcgccac ctccccccgg cctgggcagc gctcgcccgg ggagtccagc
61 ggtgtcctgt ggagctgccg ccatggcccc gcggcgggcg cgcggctgcc ggaccctcgg
121 tctcccggcg ctgctactgc tgctgctgct ccggccgccg gcgacgcggg gcatcacgtg
181 ccctcccccc atgtccgtgg aacacgcaga catctgggtc aagagctaca gcttgtactc
241 cagggagcgg tacatttgta actctggttt caagcgtaaa gccggcacgt ccagcctgac
301 ggagtgcgtg ttgaacaagg ccacgaatgt cgcccactgg acaaccccca gtctcaaatg
361 cattagagac cctgccctgg ttcaccaaag gccagcgcca ccctccacag taacgacggc
421 aggggtgacc ccacagccag agagcctctc cccttctgga aaagagcccg cagcttcatc
481 tcccagctca aacaacacag cggccacaac agcagctatt gtcccgggct cccagctgat
541 gccttcaaaa tcaccttcca caggaaccac agagataagc agtcatgagt cctcccacgg
601 caccccctct cagacaacag ccaagaactg ggaactcaca gcatccgcct cccaccagcc
661 gccaggtgtg tatccacagg gccacagcga caccactgtg gctatctcca cgtccactgt
721 cctgctgtgt gggctgagcg ctgtgtctct cctggcatgc tacctcaagt caaggcaaac
781 tcccccgctg gccagcgttg aaatggaagc catggaggct ctgccggtga cttgggggac
841 cagcagcaga gatgaagact tggaaaactg ctctcaccac ctatgaaact cggggaaacc
901 agcccagcta agtccggagt gaaggagcct ctctgcttta gctaaagacg actgagaaga
961 ggtgcaagga agcgggctcc aggagcaagc tcaccaggcc tctcagaagt cccagcagga
1021 tctcacggac tgccgggtcg gcgcctcctg cgcgagggag caggttctcc gcattcccat
1081 gggcaccacc tgcctgcctg tcgtgccttg gacccagggc ccagcttccc aggagagacc
1141 aaaggcttct gagcaggatt tttatttcat tacagtgtga gctgcctgga atacatgtgg
1201 taatgaaata aaaaccctgc cccgaatctt ccgtccctca tcctaacttt cagttcacag
1261 agaaaagtga catacccaaa gctctctgtc aattacaagg cttctcctgg cgtgggagac
1321 gtctacaggg aagacaccag cgtttgggct tctaaccacc ctgtctccag ctgctctgca
1381 cacatggaca gggacctggg aaaggtggga gagatgctga gcccagcgaa tcctctccat
1441 tgaaggattc aggaagaaga aaactcaact cagtgccatt ttacgaatat atgcgtttat
1501 atttatactt ccttgtctat tatatctata cattatatat tatttgtatt ttgacattgt
1561 accttgtata aacaaaataa aacatctatt ttcaatattt ttaaaatgca
SEQ ID NO:6
interleukin 15 receptor, alpha isoform 1 precursor [Homo
sapiens] – GenBank Accession No. NP_002180
1 maprrargcr tlglpallll lllrppatrg itcpppmsve hadiwvksys lysreryicn
61 sgfkrkagts sltecvlnka tnvahwttps lkcirdpalv hqrpappstv ttagvtpqpe
121 slspsgkepa asspssnnta attaaivpgs qlmpskspst gtteisshes shgtpsqtta
181 knweltasas hqppgvypqg hsdttvaist stvllcglsa vsllacylks rqtpplasve
241 meamealpvt wgtssrdedl encshhl
SEQ ID NO:7
Homo sapiens interleukin 15 receptor, alpha (IL15RA),
transcript variant 2, mRNA – GenBank Accession No. NM_172200
1 caggaattcg gcgaagtggc ggagctgggg ccccagcggg cgccgggggc cgcgggagcc
61 agcaggtggc gggggctgcg ctccgcccgg gccagagcgc accaggcagg tgcccgcgcc
121 tccgcaccgc ggcgacacct ccgcgggcac tcacccaggc cggccgctca caaccgagcg
181 cagggccgcg gagggagacc aggaaagccg aaggcggagc agctggaggc gaccagcgcc
241 gggcgaggtc aagtggatcc gagccgcaga gagggctgga gagagtctgc tctccgatga
301 ctttgcccac tctcttcgca gtggggacac cggaccgagt gcacactgga ggtcccagag
361 cacgacgagc gcggaggacc gggaggctcc cgggcttgcg tgggcatcac gtgccctccc
421 cccatgtccg tggaacacgc agacatctgg gtcaagagct acagcttgta ctccagggag
481 cggtacattt gtaactctgg tttcaagcgt aaagccggca cgtccagcct gacggagtgc
541 gtgttgaaca aggccacgaa tgtcgcccac tggacaaccc ccagtctcaa atgcattaga
601 gaccctgccc tggttcacca aaggccagcg ccaccctcca cagtaacgac ggcaggggtg
661 accccacagc cagagagcct ctccccttct ggaaaagagc ccgcagcttc atctcccagc
721 tcaaacaaca cagcggccac aacagcagct attgtcccgg gctcccagct gatgccttca
781 aaatcacctt ccacaggaac cacagagata agcagtcatg agtcctccca cggcaccccc
841 tctcagacaa cagccaagaa ctgggaactc acagcatccg cctcccacca gccgccaggt
901 gtgtatccac agggccacag cgacaccact gtggctatct ccacgtccac tgtcctgctg
961 tgtgggctga gcgctgtgtc tctcctggca tgctacctca agtcaaggca aactcccccg
1021 ctggccagcg ttgaaatgga agccatggag gctctgccgg tgacttgggg gaccagcagc
1081 agagatgaag acttggaaaa ctgctctcac cacctatgaa actcggggaa accagcccag
1141 ctaagtccgg agtgaaggag cctctctgct ttagctaaag acgactgaga agaggtgcaa
1201 ggaagcgggc tccaggagca agctcaccag gcctctcaga agtcccagca ggatctcacg
1261 gactgccggg tcggcgcctc ctgcgcgagg gagcaggttc tccgcattcc catgggcacc
1321 acctgcctgc ctgtcgtgcc ttggacccag ggcccagctt cccaggagag accaaaggct
1381 tctgagcagg atttttattt cattacagtg tgagctgcct ggaatacatg tggtaatgaa
1441 ataaaaaccc tgccccgaat cttccgtccc tcatcctaac tttcagttca cagagaaaag
1501 tgacataccc aaagctctct gtcaattaca aggcttctcc tggcgtggga gacgtctaca
1561 gggaagacac cagcgtttgg gcttctaacc accctgtctc cagctgctct gcacacatgg
1621 acagggacct gggaaaggtg ggagagatgc tgagcccagc gaatcctctc cattgaagga
1681 ttcaggaaga agaaaactca actcagtgcc attttacgaa tatatgcgtt tatatttata
1741 cttccttgtc tattatatct atacattata tattatttgt attttgacat tgtaccttgt
1801 ataaacaaaa taaaacatct attttcaata tttttaaaat gca
SEQ ID NO:8
interleukin 15 receptor, alpha isoform 2 [Homo sapiens] –
GenBank Accession No. NP_751950
1 msvehadiwv ksyslysrer yicnsgfkrk agtssltecv lnkatnvahw ttpslkcird
61 palvhqrpap pstvttagvt pqpeslspsg kepaasspss nntaattaai vpgsqlmpsk
121 spstgtteis shesshgtps qttaknwelt asashqppgv ypqghsdttv aiststvllc
181 glsavsllac ylksrqtppl asvemeamea lpvtwgtssr dedlencshh l
SEQ ID NO:9
Improved human interleukin 15 (IL-15) receptor alpha (IL15Ra),
transcript variant 1 (OPT)
atggccccga ggcgggcgcg aggctgccgg accctcggtc tcccggcgct gctactgctc 60
ctgctgctcc ggccgccggc gacgcggggc atcacgtgcc cgccccccat gtccgtggag 120
cacgcagaca tctgggtcaa gagctacagc ttgtactccc gggagcggta catctgcaac 180
tcgggtttca agcggaaggc cggcacgtcc agcctgacgg agtgcgtgtt gaacaaggcc 240
acgaatgtcg cccactggac gaccccctcg ctcaagtgca tccgcgaccc ggccctggtt 300
caccagcggc ccgcgccacc ctccaccgta acgacggcgg gggtgacccc gcagccggag 360
agcctctccc cgtcgggaaa ggagcccgcc gcgtcgtcgc ccagctcgaa caacacggcg 420
gccacaactg cagcgatcgt cccgggctcc cagctgatgc cgtcgaagtc gccgtccacg 480
ggaaccacgg agatcagcag tcatgagtcc tcccacggca ccccctcgca aacgacggcc 540
aagaactggg aactcacggc gtccgcctcc caccagccgc cgggggtgta tccgcaaggc 600
cacagcgaca ccacggtggc gatctccacg tccacggtcc tgctgtgtgg gctgagcgcg 660
gtgtcgctcc tggcgtgcta cctcaagtcg aggcagactc ccccgctggc cagcgttgag 720
atggaggcca tggaggctct gccggtgacg tgggggacca gcagcaggga tgaggacttg 780
gagaactgct cgcaccacct ataatga 807
SEQ ID NO:10 - improved human interleukin 15 (IL-15) receptor
alpha (IL15Ra), transcript variant 1 (OPT)
Met Ala Pro Arg Arg Ala Arg Gly Cys Arg Thr Leu Gly Leu Pro Ala
1 5 10 15
Leu Leu Leu Leu Leu Leu Leu Arg Pro Pro Ala Thr Arg Gly Ile Thr
25 30
Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser
40 45
Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys
50 55 60
Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala
65 70 75 80
Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile Arg Asp
85 90 95
Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val Thr Thr
100 105 110
Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly Lys Glu
115 120 125
Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala
130 135 140
Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr
145 150 155 160
Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser
165 170 175
Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln
180 185 190
Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr Val Ala Ile
195 200 205
Ser Thr Ser Thr Val Leu Leu Cys Gly Leu Ser Ala Val Ser Leu Leu
210 215 220
Ala Cys Tyr Leu Lys Ser Arg Gln Thr Pro Pro Leu Ala Ser Val Glu
225 230 235 240
Met Glu Ala Met Glu Ala Leu Pro Val Thr Trp Gly Thr Ser Ser Arg
245 250 255
Asp Glu Asp Leu Glu Asn Cys Ser His His Leu
260 265
SEQ ID NO:11 - improved human soluble interleukin 15 (IL-15)
receptor alpha (IL-15sRa) (OPT)
atggccccga ggcgggcgcg aggctgccgg accctcggtc tcccggcgct gctactgctc 60
ctgctgctcc ggccgccggc gacgcggggc atcacgtgcc cgccccccat gtccgtggag 120
cacgcagaca tctgggtcaa gagctacagc ttgtactccc gggagcggta catctgcaac 180
tcgggtttca agcggaaggc cggcacgtcc agcctgacgg agtgcgtgtt gaacaaggcc 240
acgaatgtcg cccactggac gaccccctcg ctcaagtgca tccgcgaccc ggccctggtt 300
caccagcggc ccgcgccacc ctccaccgta acgacggcgg gggtgacccc gcagccggag 360
agcctctccc cgtcgggaaa ggagcccgcc gcgtcgtcgc ccagctcgaa caacacggcg 420
gccacaactg cagcgatcgt cccgggctcc cagctgatgc cgtcgaagtc gccgtccacg 480
ggaaccacgg agatcagcag tcatgagtcc tcccacggca ccccctcgca aacgacggcc 540
aagaactggg aactcacggc gtccgcctcc caccagccgc cgggggtgta tccgcaaggc 600
cacagcgaca ccacgtaatg a 621
SEQ ID NO:12 - improved human soluble interleukin 15 (IL-15)
receptor alpha (IL-15sRa) (OPT)
Met Ala Pro Arg Arg Ala Arg Gly Cys Arg Thr Leu Gly Leu Pro Ala
1 5 10 15
Leu Leu Leu Leu Leu Leu Leu Arg Pro Pro Ala Thr Arg Gly Ile Thr
25 30
Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val Lys Ser
40 45
Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly Phe Lys
50 55 60
Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn Lys Ala
65 70 75 80
Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile Arg Asp
85 90 95
Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val Thr Thr
100 105 110
Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly Lys Glu
115 120 125
Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr Thr Ala
130 135 140
Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro Ser Thr
145 150 155 160
Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr Pro Ser
165 170 175
Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser His Gln
180 185 190
Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp Thr Thr
195 200 205
SEQ ID NO:13
Dual expression plasmid human IL15Ra+IL15
CCTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCA
ACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTC
ATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTG
GCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACG
CCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGC
AGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGC
CCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC
GTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA
GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTT
GGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATG
GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGAT
CGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCC
TCCGCGGGCGCGCGTCGAGGAATTCGCTAGCAAGAAATGGCCCCGAGGCGGGCGCGAGGCTG
CCGGACCCTCGGTCTCCCGGCGCTGCTACTGCTCCTGCTGCTCCGGCCGCCGGCGACGCGGG
GCATCACGTGCCCGCCCCCCATGTCCGTGGAGCACGCAGACATCTGGGTCAAGAGCTACAGC
TTGTACTCCCGGGAGCGGTACATCTGCAACTCGGGTTTCAAGCGGAAGGCCGGCACGTCCAG
CCTGACGGAGTGCGTGTTGAACAAGGCCACGAATGTCGCCCACTGGACGACCCCCTCGCTCA
AGTGCATCCGCGACCCGGCCCTGGTTCACCAGCGGCCCGCGCCACCCTCCACCGTAACGACG
GCGGGGGTGACCCCGCAGCCGGAGAGCCTCTCCCCGTCGGGAAAGGAGCCCGCCGCGTCGTC
GCCCAGCTCGAACAACACGGCGGCCACAACTGCAGCGATCGTCCCGGGCTCCCAGCTGATGC
CGTCGAAGTCGCCGTCCACGGGAACCACGGAGATCAGCAGTCATGAGTCCTCCCACGGCACC
CCCTCGCAAACGACGGCCAAGAACTGGGAACTCACGGCGTCCGCCTCCCACCAGCCGCCGGG
GGTGTATCCGCAAGGCCACAGCGACACCACGGTGGCGATCTCCACGTCCACGGTCCTGCTGT
GTGGGCTGAGCGCGGTGTCGCTCCTGGCGTGCTACCTCAAGTCGAGGCAGACTCCCCCGCTG
GCCAGCGTTGAGATGGAGGCCATGGAGGCTCTGCCGGTGACGTGGGGGACCAGCAGCAGGGA
TGAGGACTTGGAGAACTGCTCGCACCACCTATAATGAGAATTCACGCGTGGATCTGATATCG
GATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTG
ACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTG
TCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATT
GGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGGTACCCAGGTGCTGAAG
AATTGACCCGGTTCCTCCTGGGCCAGAAAGAAGCAGGCACATCCCCTTCTCTGTGACACACC
CTGTCCACGCCCCTGGTTCTTAGTTCCAGCCCCACTCATAGGACACTCATAGCTCAGGAGGG
CTCCGCCTTCAATCCCACCCGCTAAAGTACTTGGAGCGGTCTCTCCCTCCCTCATCAGCCCA
CCAAACCAAACCTAGCCTCCAAGAGTGGGAAGAAATTAAAGCAAGATAGGCTATTAAGTGCA
GAGGGAGAGAAAATGCCTCCAACATGTGAGGAAGTAATGAGAGAAATCATAGAATTTCTTCC
GCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCA
CTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAG
CAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGG
CTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGAC
AGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGA
CCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAA
TGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCA
CGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACC
CGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGG
TATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGAC
AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTT
GATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACG
CGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTG
GAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA
TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCT
GACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATC
CATAGTTGCCTGACTCGGGGGGGGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTG
ACTCATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTTGATG
AGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCACGGAACGGTC
TGCGTTGTCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATTCAAC
AAAGCCGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATTAACCAATT
CTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCA
ATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCA
TAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTA
TTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAA
TCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATT
ACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAG
CGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGG
CGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATAC
CTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGA
TAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCA
TCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGG
CTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTAT
ACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGT
TGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCA
TGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGATCA
TCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAA
AATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAAT
AAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGA
GGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCGTCGAGGAT
CTGGATCCGTTAACCGATATCCGCGAATTCGGCGCGCCGGGCCCTCACGACGTGTTGATGAA
CATCTGGACGATGTGCACGAACGACTGCAGGAACTCCTTGATGTTCTTCTCCTCCAGCTCCT
CGCACTCCTTGCAGCCCGACTCCGTGACGTTCCCGTTCGACGACAGCGAGTTGTTCGCCAGG
ATGATCAGGTTCTCCACCGTGTCGTGGATCGACGCGTCCCCCGACTCGAGCGAGATGACTTG
GAGCTCCAGGAGGAAGCACTTCATCGCCGTGACCTTGCACGACGGGTGGACGTCCGACTCCG
TGTACAGCGTCGCGTCGATGTGCATCGACTGGATGAGGTCCTCGATCTTCTTCAGGTCCGAG
ATCACGTTCACCCAGTTCGCCTCCGTCTTCGGCAGCCCCGCCGAGAAGCAGCCCAGGATGAA
GACGTGTATACCGGCCTCCGTGAGGAAGTGCGAGTTCAGGAGCAGGCACAGGTAGCACTGGA
TCGATATCGACCGCAGGTGCGGCTTCGAGATCCGCATTTCTTGTCGACACTCGACAGATCCA
AACGCTCCTCCGACGTCCCCAGGCAGAATGGCGGTTCCCTAAACGAGCATTGCTTATATAGA
CCTCCCATTAGGCACGCCTACCGCCCATTTACGTCAATGGAACGCCCATTTGCGTCATTGCC
CCTCCCCATTGACGTCAATGGGGATGTACTTGGCAGCCATCGCGGGCCATTTACCGCCATTG
ACGTCAATGGGAGTACTGCCAATGTACCCTGGCGTACTTCCAATAGTAATGTACTTGCCAAG
TTACTATTAATAGATATTGATGTACTGCCAAGTGGGCCATTTACCGTCATTGACGTCAATAG
GGGGCGTGAGAACGGATATGAATGGGCAATGAGCCATCCCATTGACGTCAATGGTGGGTGGT
CCTATTGACGTCAATGGGCATTGAGCCAGGCGGGCCATTTACCGTAATTGACGTCAATGGGG
GAGGCGCCATATACGTCAATAGGACCGCCCATATGACGTCAATAGGAAAGACCATGAGGCCC
TTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGAC
GGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGG
GTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTG
CACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGATTGGC
TATTGG
SEQ ID NO:14
Dual expression plasmid human IL15Ra+IL15tPA6
CCTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCA
ACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTC
ATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTG
GCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACG
CCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGC
AGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGC
CCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC
GTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA
GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTT
GGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATG
GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGAT
CGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCC
TCCGCGGGCGCGCGTCGAGGAATTCGCTAGCAAGAAATGGCCCCGAGGCGGGCGCGAGGCTG
CCGGACCCTCGGTCTCCCGGCGCTGCTACTGCTCCTGCTGCTCCGGCCGCCGGCGACGCGGG
GCATCACGTGCCCGCCCCCCATGTCCGTGGAGCACGCAGACATCTGGGTCAAGAGCTACAGC
TTGTACTCCCGGGAGCGGTACATCTGCAACTCGGGTTTCAAGCGGAAGGCCGGCACGTCCAG
CCTGACGGAGTGCGTGTTGAACAAGGCCACGAATGTCGCCCACTGGACGACCCCCTCGCTCA
AGTGCATCCGCGACCCGGCCCTGGTTCACCAGCGGCCCGCGCCACCCTCCACCGTAACGACG
GCGGGGGTGACCCCGCAGCCGGAGAGCCTCTCCCCGTCGGGAAAGGAGCCCGCCGCGTCGTC
GCCCAGCTCGAACAACACGGCGGCCACAACTGCAGCGATCGTCCCGGGCTCCCAGCTGATGC
CGTCGAAGTCGCCGTCCACGGGAACCACGGAGATCAGCAGTCATGAGTCCTCCCACGGCACC
CCCTCGCAAACGACGGCCAAGAACTGGGAACTCACGGCGTCCGCCTCCCACCAGCCGCCGGG
GGTGTATCCGCAAGGCCACAGCGACACCACGGTGGCGATCTCCACGTCCACGGTCCTGCTGT
GTGGGCTGAGCGCGGTGTCGCTCCTGGCGTGCTACCTCAAGTCGAGGCAGACTCCCCCGCTG
GCCAGCGTTGAGATGGAGGCCATGGAGGCTCTGCCGGTGACGTGGGGGACCAGCAGCAGGGA
TGAGGACTTGGAGAACTGCTCGCACCACCTATAATGAGAATTCACGCGTGGATCTGATATCG
GATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTG
ACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTG
TCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATT
GGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGGTACCCAGGTGCTGAAG
AATTGACCCGGTTCCTCCTGGGCCAGAAAGAAGCAGGCACATCCCCTTCTCTGTGACACACC
CTGTCCACGCCCCTGGTTCTTAGTTCCAGCCCCACTCATAGGACACTCATAGCTCAGGAGGG
CTCCGCCTTCAATCCCACCCGCTAAAGTACTTGGAGCGGTCTCTCCCTCCCTCATCAGCCCA
CCAAACCAAACCTAGCCTCCAAGAGTGGGAAGAAATTAAAGCAAGATAGGCTATTAAGTGCA
GAGGGAGAGAAAATGCCTCCAACATGTGAGGAAGTAATGAGAGAAATCATAGAATTTCTTCC
GCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCA
CTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAG
CAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGG
CTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGAC
AGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGA
CCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAA
TGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCA
CGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACC
CGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGG
TATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGAC
AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTT
GATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACG
CGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTG
GAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA
TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCT
GACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATC
CATAGTTGCCTGACTCGGGGGGGGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTG
ACTCATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTTGATG
AGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCACGGAACGGTC
TGCGTTGTCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATTCAAC
AAAGCCGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATTAACCAATT
CTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCA
ATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCA
TAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTA
TTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAA
TCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATT
ACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAG
CGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGG
CGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATAC
CTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGA
TAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCA
TCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGG
CTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTAT
ACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGT
TGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCA
TGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGATCA
TCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAA
AATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAAT
AAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGA
GGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCGTCGAGGAT
CTGGATCTGGATCCGTTAACCGATATCCGCGAATTCGGCGCGCCGGGCCCTCACGACGTGTT
GATGAACATCTGGACGATGTGCACGAACGACTGCAGGAACTCCTTGATGTTCTTCTCCTCCA
GCTCCTCGCACTCCTTGCAGCCCGACTCCGTGACGTTCCCGTTCGACGACAGCGAGTTGTTC
GCCAGGATGATCAGGTTCTCCACCGTGTCGTGGATCGACGCGTCCCCCGACTCGAGCGAGAT
GACTTGGAGCTCCAGGAGGAAGCACTTCATCGCCGTGACCTTGCACGACGGGTGGACGTCCG
ACTCCGTGTACAGCGTCGCGTCGATGTGCATCGACTGGATGAGGTCCTCGATCTTCTTCAGG
TCCGAGATCACGTTCACCCAGTTTCTGGCTCCTCTTCTGAATCGGGCATGGATTTCCTGGCT
GGGCGAAACGAAGACTGCTCCACACAGCAGCAGCACACAGCAGAGCCCTCTCTTCATTGCAT
CCATTTCTTGTCGACAGATCCAAACGCTCCTCCGACGTCCCCAGGCAGAATGGCGGTTCCCT
AAACGAGCATTGCTTATATAGACCTCCCATTAGGCACGCCTACCGCCCATTTACGTCAATGG
AACGCCCATTTGCGTCATTGCCCCTCCCCATTGACGTCAATGGGGATGTACTTGGCAGCCAT
CGCGGGCCATTTACCGCCATTGACGTCAATGGGAGTACTGCCAATGTACCCTGGCGTACTTC
CAATAGTAATGTACTTGCCAAGTTACTATTAATAGATATTGATGTACTGCCAAGTGGGCCAT
TTACCGTCATTGACGTCAATAGGGGGCGTGAGAACGGATATGAATGGGCAATGAGCCATCCC
ATTGACGTCAATGGTGGGTGGTCCTATTGACGTCAATGGGCATTGAGCCAGGCGGGCCATTT
ACCGTAATTGACGTCAATGGGGGAGGCGCCATATACGTCAATAGGACCGCCCATATGACGTC
AATAGGAAAGACCATGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCT
GACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAA
GCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATC
AGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGA
GAAAATACCGCATCAGATTGGCTATTGG
SEQ ID NO:15
Dual expression plasmid human IL15sRa(soluble)+IL15tPA6
CCTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCA
ACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTC
ATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTG
GCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACG
CCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGC
AGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGC
CCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTAC
GTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATA
GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTT
GGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATG
GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGAT
CGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCC
TCCGCGGGCGCGCGTCGAGGAATTCGCTAGCAAGAAATGGCCCCGAGGCGGGCGCGAGGCTG
CCGGACCCTCGGTCTCCCGGCGCTGCTACTGCTCCTGCTGCTCCGGCCGCCGGCGACGCGGG
GCATCACGTGCCCGCCCCCCATGTCCGTGGAGCACGCAGACATCTGGGTCAAGAGCTACAGC
TTGTACTCCCGGGAGCGGTACATCTGCAACTCGGGTTTCAAGCGGAAGGCCGGCACGTCCAG
CCTGACGGAGTGCGTGTTGAACAAGGCCACGAATGTCGCCCACTGGACGACCCCCTCGCTCA
AGTGCATCCGCGACCCGGCCCTGGTTCACCAGCGGCCCGCGCCACCCTCCACCGTAACGACG
GCGGGGGTGACCCCGCAGCCGGAGAGCCTCTCCCCGTCGGGAAAGGAGCCCGCCGCGTCGTC
GCCCAGCTCGAACAACACGGCGGCCACAACTGCAGCGATCGTCCCGGGCTCCCAGCTGATGC
CGTCGAAGTCGCCGTCCACGGGAACCACGGAGATCAGCAGTCATGAGTCCTCCCACGGCACC
CCCTCGCAAACGACGGCCAAGAACTGGGAACTCACGGCGTCCGCCTCCCACCAGCCGCCGGG
GGTGTATCCGCAAGGCCACAGCGACACCACGTAATGAGAATTCGCGGATATCGGTTAACGGA
TCCAGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTC
CTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGC
ATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAG
GATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGGTACCCAGGTGCT
GAAGAATTGACCCGGTTCCTCCTGGGCCAGAAAGAAGCAGGCACATCCCCTTCTCTGTGACA
CACCCTGTCCACGCCCCTGGTTCTTAGTTCCAGCCCCACTCATAGGACACTCATAGCTCAGG
AGGGCTCCGCCTTCAATCCCACCCGCTAAAGTACTTGGAGCGGTCTCTCCCTCCCTCATCAG
CCCACCAAACCAAACCTAGCCTCCAAGAGTGGGAAGAAATTAAAGCAAGATAGGCTATTAAG
TGCAGAGGGAGAGAAAATGCCTCCAACATGTGAGGAAGTAATGAGAGAAATCATAGAATTTC
TTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAG
CTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATG
TGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCA
TAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACC
CGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTT
CCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTC
TCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTG
TGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCC
AACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGC
GAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAA
GGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGC
TCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGAT
TACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTC
AGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACC
TAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTG
GTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTT
CATCCATAGTTGCCTGACTCGGGGGGGGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTT
GCTGACTCATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTT
GATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTTGAACTTTTGCTTTGCCACGGAAC
GGTCTGCGTTGTCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTCGATTTATT
CAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATTAACC
AATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATT
ATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGT
TCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAA
CCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGAC
TGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGC
CATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCC
TGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAA
CCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTA
ATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTA
CGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCAT
CTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCAT
CGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCAT
TTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTC
CCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTG
TTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGG
ATCATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA
AAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTG
CAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGT
GGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCGTCGA
GGATCTGGATCTGGATCCGTTAACCGATATCCGCGAATTCGGCGCGCCGGGCCCTCACGACG
TGTTGATGAACATCTGGACGATGTGCACGAACGACTGCAGGAACTCCTTGATGTTCTTCTCC
TCCAGCTCCTCGCACTCCTTGCAGCCCGACTCCGTGACGTTCCCGTTCGACGACAGCGAGTT
GTTCGCCAGGATGATCAGGTTCTCCACCGTGTCGTGGATCGACGCGTCCCCCGACTCGAGCG
AGATGACTTGGAGCTCCAGGAGGAAGCACTTCATCGCCGTGACCTTGCACGACGGGTGGACG
TCCGACTCCGTGTACAGCGTCGCGTCGATGTGCATCGACTGGATGAGGTCCTCGATCTTCTT
CAGGTCCGAGATCACGTTCACCCAGTTTCTGGCTCCTCTTCTGAATCGGGCATGGATTTCCT
GGCTGGGCGAAACGAAGACTGCTCCACACAGCAGCAGCACACAGCAGAGCCCTCTCTTCATT
GCATCCATTTCTTGTCGACAGATCCAAACGCTCCTCCGACGTCCCCAGGCAGAATGGCGGTT
CCCTAAACGAGCATTGCTTATATAGACCTCCCATTAGGCACGCCTACCGCCCATTTACGTCA
ATGGAACGCCCATTTGCGTCATTGCCCCTCCCCATTGACGTCAATGGGGATGTACTTGGCAG
CCATCGCGGGCCATTTACCGCCATTGACGTCAATGGGAGTACTGCCAATGTACCCTGGCGTA
CTTCCAATAGTAATGTACTTGCCAAGTTACTATTAATAGATATTGATGTACTGCCAAGTGGG
CCATTTACCGTCATTGACGTCAATAGGGGGCGTGAGAACGGATATGAATGGGCAATGAGCCA
TCCCATTGACGTCAATGGTGGGTGGTCCTATTGACGTCAATGGGCATTGAGCCAGGCGGGCC
ATTTACCGTAATTGACGTCAATGGGGGAGGCGCCATATACGTCAATAGGACCGCCCATATGA
CGTCAATAGGAAAGACCATGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAAC
CTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAG
ACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGG
CATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTA
AGGAGAAAATACCGCATCAGATTGGCTATTGG
SEQ ID NO:16--DPhuIL15sRa205FC+huGMIL15 The capitalized, bolded
region is the coding region for the IL-15Receptor alpha 205FC
fusion
cctggccattgcatacgttgtatccatatcataatatgtacatttatattggctcatgtcca
acattaccgccatgttgacattgattattgactagttattaatagtaatcaattacggggtc
attagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctg
gctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacg
ccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggc
agtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgatggtaaatggc
ccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctac
gtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata
gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgtttt
ggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatg
ggcggtaggcgtgtacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagat
cgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcc
tccgcgggcgcgcgtcgacgctagcaagaaATGGCCCCGAGGCGGGCGCGAGGCTGCCGGAC
CCTCGGTCTCCCGGCGCTGCTACTGCTCCTGCTGCTCCGGCCGCCGGCGACGCGGGGCATCA
CGTGCCCGCCCCCCATGTCCGTGGAGCACGCAGACATCTGGGTCAAGAGCTACAGCTTGTAC
TCCCGGGAGCGGTACATCTGCAACTCGGGTTTCAAGCGGAAGGCCGGCACGTCCAGCCTGAC
GGAGTGCGTGTTGAACAAGGCCACGAATGTCGCCCACTGGACGACCCCCTCGCTCAAGTGCA
TCCGCGACCCGGCCCTGGTTCACCAGCGGCCCGCGCCACCCTCCACCGTAACGACGGCGGGG
GTGACCCCGCAGCCGGAGAGCCTCTCCCCGTCGGGAAAGGAGCCCGCCGCGTCGTCGCCCAG
CTCGAACAACACGGCGGCCACAACTGCAGCGATCGTCCCGGGCTCCCAGCTGATGCCGTCGA
AGTCGCCGTCCACGGGAACCACGGAGATCAGCAGTCATGAGTCCTCCCACGGCACCCCCTCG
CAAACGACGGCCAAGAACTGGGAACTCACGGCGTCCGCCTCCCACCAGCCGCCGGGGGTGTA
TCCGCAAGGCCACAGCGACACCACGCCGAAGTCCTGCGACAAGACGCACACGTGCCCTCCCT
GCCCGGCGCCCGAGCTGCTGGGAGGTCCGAGCGTGTTCCTCTTCCCGCCCAAGCCGAAGGAC
ACGCTCATGATCTCGCGGACTCCCGAGGTCACCTGCGTCGTGGTAGACGTCAGCCACGAGGA
CCCGGAGGTCAAGTTCAACTGGTACGTTGACGGCGTAGAGGTGCACAACGCGAAGACGAAGC
CGCGGGAGGAGCAGTACAACTCGACGTACCGAGTCGTGTCGGTCCTGACCGTCCTGCACCAG
GACTGGCTCAACGGGAAGGAGTACAAGTGCAAGGTGTCGAACAAGGCGCTCCCTGCCCCGAT
CGAGAAGACGATCTCGAAGGCGAAGGGCCAGCCCAGGGAGCCCCAGGTCTACACGCTCCCGC
CATCGCGGGACGAGCTGACGAAGAACCAGGTTTCCCTGACGTGCCTCGTCAAGGGCTTCTAC
CCATCGGACATCGCGGTGGAGTGGGAGAGCAACGGGCAGCCGGAGAACAACTACAAGACCAC
GCCTCCGGTGCTCGACTCGGACGGGTCGTTCTTCCTCTACTCGAAGCTGACCGTCGACAAGA
GCCGGTGGCAGCAGGGCAACGTGTTCTCCTGCTCGGTGATGCACGAGGCCCTCCACAACCAC
TACACCCAGAAGTCGCTCAGTCTGAGCCCGGGGAAGTAATGAggatccgaattcgcggatat
cggttaacggatccagatctgctgtgccttctagttgccagccatctgttgtttgcccctcc
cccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgagga
aattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggaca
gcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatgggt
acccaggtgctgaagaattgacccggttcctcctgggccagaaagaagcaggcacatcccct
tctctgtgacacaccctgtccacgcccctggttcttagttccagccccactcataggacact
catagctcaggagggctccgccttcaatcccacccgctaaagtacttggagcggtctctccc
tccctcatcagcccaccaaaccaaacctagcctccaagagtgggaagaaattaaagcaagat
aggctattaagtgcagagggagagaaaatgcctccaacatgtgaggaagtaatgagagaaat
catagaatttcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcg
agcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcag
gaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctg
gcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagag
gtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgc
gctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagc
gtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaa
gctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatc
gtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacagg
attagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacgg
ctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaa
gagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgc
aagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggg
gtctgacgctcagtggaacgaaaact
cacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaat
taaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttacca
atgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcct
gactcggggggggggggcgctgaggtctgcctcgtgaagaaggtgttgctgactcataccag
gcctgaatcgccccatcatccagccagaaagtgagggagccacggttgatgagagctttgtt
gtaggtggaccagttggtgattttgaacttttgctttgccacggaacggtctgcgttgtcgg
gaagatgcgtgatctgatccttcaactcagcaaaagttcgatttattcaacaaagccgccgt
cccgtcaagtcagcgtaatgctctgccagtgttacaaccaattaaccaattctgattagaaa
aactcatcgagcatcaaatgaaactgcaatttattcatatcaggattatcaataccatattt
ttgaaaaagccgtttctgtaatgaaggagaaaactcaccgaggcagttccataggatggcaa
gatcctggtatcggtctgcgattccgactcgtccaacatcaatacaacctattaatttcccc
tcgtcaaaaataaggttatcaagtgagaaatcaccatgagtgacgactgaatccggtgagaa
tggcaaaagcttatgcatttctttccagacttgttcaacaggccagccattacgctcgtcat
caaaatcactcgcatcaaccaaaccgttattcattcgtgattgcgcctgagcgagacgaaat
acgcgatcgctgttaaaaggacaattacaaacaggaatcgaatgcaaccggcgcaggaacac
tgccagcgcatcaacaatattttcacctgaatcaggatattcttctaatacctggaatgctg
ttttcccggggatcgcagtggtgagtaaccatgcatcatcaggagtacggataaaatgcttg
atggtcggaagaggcataaattccgtcagccagtttagtctgaccatctcatctgtaacatc
attggcaacgctacctttgccatgtttcagaaacaactctggcgcatcgggcttcccataca
atcgatagattgtcgcacctgattgcccgacattatcgcgagcccatttatacccatataaa
tcagcatccatgttggaatttaatcgcggcctcgagcaagacgtttcccgttgaatatggct
cataacaccccttgtattactgtttatgtaagcagacagttttattgttcatgatgatatat
ttttatcttgtgcaatgtaacatcagagattttgagacacaacgtggatcatccagacatga
taagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaatgctttatt
tgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagttaa
caacaacaattgcattcattttatgtttcaggttcagggggaggtgtgggaggttttttaaa
gcaagtaaaacctctacaaatgtggtatggctgattatgatcgtcgaggatctggatccgtt
aaccgatatccgcgaattcggcgcgccgggcccTCACGACGTGTTGATGAACATCTGGACGA
TGTGCACGAACGACTGCAGGAACTCCTTGATGTTCTTCTCCTCCAGCTCCTCGCACTCCTTG
CAGCCCGACTCCGTGACGTTCCCGTTCGACGACAGCGAGTTGTTCGCCAGGATGATCAGGTT
CTCCACCGTGTCGTGGATCGACGCGTCCCCCGACTCGAGCGAGATGACTTGGAGCTCCAGGA
GGAAGCACTTCATCGCCGTGACCTTGCACGACGGGTGGACGTCCGACTCCGTGTACAGCGTC
GCGTCGATGTGCATCGACTGGATGAGGTCCTCGATCTTCTTCAGGTCCGAGATCACGTTCAC
CCAGTTCGAGATGCTGCAGGCCACCGTCCCCAGGAGTAGCAGGCTCTGGAGCCACATttctt
gtcgacagatccaaacgctcctccgacgtccccaggcagaatggcggttccctaaacgagca
ttgcttatatagacctcccattaggcacgcctaccgcccatttacgtcaatggaacgcccat
ttgcgtcattgcccctccccattgacgtcaatggggatgtacttggcagccatcgcgggcca
tttaccgccattgacgtcaatgggagtactgccaatgtaccctggcgtacttccaatagtaa
tgtacttgccaagttactattaatagatattgatgtactgccaagtgggccatttaccgtca
ttgacgtcaatagggggcgtgagaacggatatgaatgggcaatgagccatcccattgacgtc
aatggtgggtggtcctattgacgtcaatgggcattgagccaggcgggccatttaccgtaatt
gacgtcaatgggggaggcgccatatacgtcaataggaccgcccatatgacgtcaataggtaa
gaccatgaggccctttcgtctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgc
agctcccggagacggtcacagcttgtctgtaagcggatgccgggagcagacaagcccgtcag
ggcgcgtcagcgggtgttggcgggtgtcggggctggcttaactatgcggcatcagagcagat
tgtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgtaaggagaaaatacc
gcatcagattggctattgg
SEQ ID NO:17--huIL15sRa205-Fc—underlined region is IL15sRa
sequence
M A P R R A R G C R T L G L P A L L L L L
L L R P P A T R G I T C P P P M S V E H A
D I W V K S Y S L Y S R E R Y I C N S G F
K R K A G T S S L T E C V L N K A T N V A
H W T T P S L K C I R D P A L V H Q R P A
P P S T V T T A G V T P Q P E S L S P S G
K E P A A S S P S S N N T A A T T A A I V
P G S Q L M P S K S P S T G T T E I S S H
E S S H G T P S Q T T A K N W E L T A S A
S H Q P P G V Y P Q G H S D T T P K S C D
K T H T C P P C P A P E L L G G P S V F L
F P P K P K D T L M I S R T P E V T C V V
V D V S H E D P E V K F N W Y V D G V E V
H N A K T K P R E E Q Y N S T Y R V V S V
L T V L H Q D W L N G K E Y K C K V S N K
A L P A P I E K T I S K A K G Q P R E P Q
V Y T L P P S R D E L T K N Q V S L T C L
V K G F Y P S D I A V E W E S N G Q P E N
N Y K T T P P V L D S D G S F F L Y S K L
T V D K S R W Q Q G N V F S C S V M H E A
L H N H Y T Q K S L S L S P G K
SEQ ID NO:18--huGMCSF-IL15
M W L Q S L L L L G T V A C S I S N W V N
V I S D L K K I E D L I Q S M H I D A T L
Y T E S D V H P S C K V T A M K C F L L E
L Q V I S L E S G D A S I H D T V E N L I
I L A N N S L S S N G N V T E S G C K E C
E E L E E K N I K E F L Q S F V H I V Q M
F I N T S
SEQ ID NO:19--AG256DPhuIL15sRa200FC+huGMIL15— The capitalized,
bolded region is the coding region for the IL-15Receptor alpha
200FC fusion
cctggccattgcatacgttgtatccatatcataatatgtacatttatattggctcatgtcca
acattaccgccatgttgacattgattattgactagttattaatagtaatcaattacggggtc
attagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctg
gctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacg
ccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggc
agtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgatggtaaatggc
ccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctac
gtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata
gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgtttt
ggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatg
ggcggtaggcgtgtacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagat
cgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatccagcc
tccgcgggcgcgcgtcgacgctagcaagaaATGGCCCCGAGGCGGGCGCGAGGCTGCCGGAC
CCTCGGTCTCCCGGCGCTGCTACTGCTCCTGCTGCTCCGGCCGCCGGCGACGCGGGGCATCA
CGTGCCCGCCCCCCATGTCCGTGGAGCACGCAGACATCTGGGTCAAGAGCTACAGCTTGTAC
TCCCGGGAGCGGTACATCTGCAACTCGGGTTTCAAGCGGAAGGCCGGCACGTCCAGCCTGAC
GGAGTGCGTGTTGAACAAGGCCACGAATGTCGCCCACTGGACGACCCCCTCGCTCAAGTGCA
TCCGCGACCCGGCCCTGGTTCACCAGCGGCCCGCGCCACCCTCCACCGTAACGACGGCGGGG
GTGACCCCGCAGCCGGAGAGCCTCTCCCCGTCGGGAAAGGAGCCCGCCGCGTCGTCGCCCAG
CTCGAACAACACGGCGGCCACAACTGCAGCGATCGTCCCGGGCTCCCAGCTGATGCCGTCGA
AGTCGCCGTCCACGGGAACCACGGAGATCAGCAGTCATGAGTCCTCCCACGGCACCCCCTCG
CAAACGACGGCCAAGAACTGGGAACTCACGGCGTCCGCCTCCCACCAGCCGCCGGGGGTGTA
TCCGCAAGGCCCGAAGTCCTGCGACAAGACGCACACGTGCCCTCCCTGCCCGGCGCCCGAGC
TGCTGGGAGGTCCGAGCGTGTTCCTCTTCCCGCCCAAGCCGAAGGACACGCTCATGATCTCG
CGGACTCCCGAGGTCACCTGCGTCGTGGTAGACGTCAGCCACGAGGACCCGGAGGTCAAGTT
CAACTGGTACGTTGACGGCGTAGAGGTGCACAACGCGAAGACGAAGCCGCGGGAGGAGCAGT
ACAACTCGACGTACCGAGTCGTGTCGGTCCTGACCGTCCTGCACCAGGACTGGCTCAACGGG
AAGGAGTACAAGTGCAAGGTGTCGAACAAGGCGCTCCCTGCCCCGATCGAGAAGACGATCTC
GAAGGCGAAGGGCCAGCCCAGGGAGCCCCAGGTCTACACGCTCCCGCCATCGCGGGACGAGC
TGACGAAGAACCAGGTTTCCCTGACGTGCCTCGTCAAGGGCTTCTACCCATCGGACATCGCG
GTGGAGTGGGAGAGCAACGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCGGTGCTCGA
CTCGGACGGGTCGTTCTTCCTCTACTCGAAGCTGACCGTCGACAAGAGCCGGTGGCAGCAGG
GCAACGTGTTCTCCTGCTCGGTGATGCACGAGGCCCTCCACAACCACTACACCCAGAAGTCG
CTCAGTCTGAGCCCGGGGAAGTAATGAggatccgaattcgcggatatcggttaacggatcca
gatctgctgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttg
accctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattg
tctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggatt
gggaagacaatagcaggcatgctggggatgcggtgggctctatgggtacccaggtgctgaag
aattgacccggttcctcctgggccagaaagaagcaggcacatccccttctctgtgacacacc
ctgtccacgcccctggttcttagttccagccccactcataggacactcatagctcaggaggg
ctccgccttcaatcccacccgctaaagtacttggagcggtctctccctccctcatcagccca
ccaaaccaaacctagcctccaagagtgggaagaaattaaagcaagataggctattaagtgca
gagggagagaaaatgcctccaacatgtgaggaagtaatgagagaaatcatagaatttcttcc
gcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctca
ctcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgag
caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccatagg
ctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgac
aggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccga
ccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcat
agctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgca
cgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacc
cggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgagg
tatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaac
agtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctctt
gatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacg
cgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtg
gaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctaga
tccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtct
gacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatc
catagttgcctgactcggggggggggggcgctgaggtctgcctcgtgaagaaggtgttgctg
actcataccaggcctgaatcgccccatcatccagccagaaagtgagggagccacggttgatg
agagctttgttgtaggtggaccagttggtgattttgaacttttgctttgccacggaacggtc
tgcgttgtcgggaagatgcgtgatctgatccttcaactcagcaaaagttcgatttattcaac
aaagccgccgtcccgtcaagtcagcgtaatgctctgccagtgttacaaccaattaaccaatt
ctgattagaaaaactcatcgagcatcaaatgaaactgcaatttattcatatcaggattatca
ataccatatttttgaaaaagccgtttctgtaatgaaggagaaaactcaccgaggcagttcca
taggatggcaagatcctggtatcggtctgcgattccgactcgtccaacatcaatacaaccta
ttaatttcccctcgtcaaaaataaggttatcaagtgagaaatcaccatgagtgacgactgaa
tccggtgagaatggcaaaagcttatgcatttctttccagacttgttcaacaggccagccatt
acgctcgtcatcaaaatcactcgcatcaaccaaaccgttattcattcgtgattgcgcctgag
cgagacgaaatacgcgatcgctgttaaaaggacaattacaaacaggaatcgaatgcaaccgg
cgcaggaacactgccagcgcatcaacaatattttcacctgaatcaggatattcttctaatac
ctggaatgctgttttcccggggatcgcagtggtgagtaaccatgcatcatcaggagtacgga
taaaatgcttgatggtcggaagaggcataaattccgtcagccagtttagtctgaccatctca
tctgtaacatcattggcaacgctacctttgccatgtttcagaaacaactctggcgcatcggg
cttcccatacaatcgatagattgtcgcacctgattgcccgacattatcgcgagcccatttat
acccatataaatcagcatccatgttggaatttaatcgcggcctcgagcaagacgtttcccgt
tgaatatggctcataacaccccttgtattactgtttatgtaagcagacagttttattgttca
tgatgatatatttttatcttgtgcaatgtaacatcagagattttgagacacaacgtggatca
tccagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaa
aatgctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaat
aaacaagttaacaacaacaattgcattcattttatgtttcaggttcagggggaggtgtggga
ggttttttaaagcaagtaaaacctctacaaatgtggtatggctgattatgatcgtcgaggat
ctggatccgttaaccgatatccgcgaattcggcgcgccgggcccTCACGACGTGTTGATGAA
CATCTGGACGATGTGCACGAACGACTGCAGGAACTCCTTGATGTTCTTCTCCTCCAGCTCCT
CGCACTCCTTGCAGCCCGACTCCGTGACGTTCCCGTTCGACGACAGCGAGTTGTTCGCCAGG
ATGATCAGGTTCTCCACCGTGTCGTGGATCGACGCGTCCCCCGACTCGAGCGAGATGACTTG
GAGCTCCAGGAGGAAGCACTTCATCGCCGTGACCTTGCACGACGGGTGGACGTCCGACTCCG
TGTACAGCGTCGCGTCGATGTGCATCGACTGGATGAGGTCCTCGATCTTCTTCAGGTCCGAG
ATCACGTTCACCCAGTTCGAGATGCTGCAGGCCACCGTCCCCAGGAGTAGCAGGCTCTGGAG
CCACATttcttgtcgacagatccaaacgctcctccgacgtccccaggcagaatggcggttcc
ctaaacgagcattgcttatatagacctcccattaggcacgcctaccgcccatttacgtcaat
ggaacgcccatttgcgtcattgcccctccccattgacgtcaatggggatgtacttggcagcc
atcgcgggccatttaccgccattgacgtcaatgggagtactgccaatgtaccctggcgtact
tccaatagtaatgtacttgccaagttactattaatagatattgatgtactgccaagtgggcc
atttaccgtcattgacgtcaatagggggcgtgagaacggatatgaatgggcaatgagccatc
ccattgacgtcaatggtgggtggtcctattgacgtcaatgggcattgagccaggcgggccat
ttaccgtaattgacgtcaatgggggaggcgccatatacgtcaataggaccgcccatatgacg
tcaataggtaagaccatgaggccctttcgtctcgcgcgtttcggtgatgacggtgaaaacct
ctgacacatgcagctcccggagacggtcacagcttgtctgtaagcggatgccgggagcagac
aagcccgtcagggcgcgtcagcgggtgttggcgggtgtcggggctggcttaactatgcggca
tcagagcagattgtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgtaag
gagaaaataccgcatcagattggctattgg
SEQ ID NO:20--huIL15sRa200-Fc
M A P R R A R G C R T L G L P A L L L L L
L L R P P A T R G I T C P P P M S V E H A
D I W V K S Y S L Y S R E R Y I C N S G F
K R K A G T S S L T E C V L N K A T N V A
H W T T P S L K C I R D P A L V H Q R P A
P P S T V T T A G V T P Q P E S L S P S G
K E P A A S S P S S N N T A A T T A A I V
P G S Q L M P S K S P S T G T T E I S S H
E S S H G T P S Q T T A K N W E L T A S A
S H Q P P G V Y P Q G P K S C D K T H T C
P P C P A P E L L G G P S V F L F P P K P
K D T L M I S R T P E V T C V V V D V S H
E D P E V K F N W Y V D G V E V H N A K T
K P R E E Q Y N S T Y R V V S V L T V L H
Q D W L N G K E Y K C K V S N K A L P A P
I E K T I S K A K G Q P R E P Q V Y T L P
P S R D E L T K N Q V S L T C L V K G F Y
P S D I A V E W E S N G Q P E N N Y K T T
P P V L D S D G S F F L Y S K L T V D K S
R W Q Q G N V F S C S V M H E A L H N H Y
T Q K S L S L S P G K
Claims (18)
1. A use of (a) an IL-15 and a soluble IL-15Rα (IL-15/IL-15sRα) complex and (b) an IL-15 and IL-15RαFc fusion protein (IL-15/IL-15RαFc) complex in the manufacture of a medicament for treating lymphopenia in a patient in need thereof.
2. The use of claim 1, wherein the IL-15Rα-Fc fusion protein of (b) comprises an amino acid sequence that has at least 95% amino acid sequence identity to the IL-15Rα-Fc fusion protein sequence of SEQ ID NO:17 or SEQ ID NO:20; or comprises an IL-15Rα-Fc fusion protein comprising SEQ ID NO:17 or SEQ ID NO:20.
3. The use of claim 1, wherein the soluble IL-15Rα of (a) comprises amino acids 31- 205 or 31-185 of native IL-15Rα.
4. The use of any one of claims 1 to 3, wherein the complex of (a) and/or the complex of (b) are to be delivered as polypeptides.
5. The use of any one of claims 1 to 3, wherein the complex of (a) and/or the complex of (b) are to be delivered as nucleic acids.
6. The use of claim 5, wherein the complex of (a) is to be delivered as a nucleic acid where the IL-15 is co-expressed from a single vector with a polynucleotide encoding the soluble IL-15Rα, and/or the complex of (b) is to be delivered as a nucleic acid where the IL- 15 is co-expressed from a single vector with a polynucleotide encoding the IL-15Rα-Fc fusion protein.
7. The use of claim 6, wherein the single vector encoding the soluble IL-15Rα comprises the nucleic acid sequence of SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and/or the single vector encoding the IL-15Rα-Fc fusion protein comprises the nucleic acid sequence of SEQ ID NO:16 or 19.
8. The use of claim 5, wherein the complex of (a) is to be delivered as a nucleic acid where the IL-15 is co-expressed from separate vectors with a polynucleotide encoding the soluble IL-15Rα.
9. The use of claim 6 or 8, wherein the polynucleotide encoding the soluble IL-15Rα has at least 90% identity to, or comprises, the nucleic acid sequence of SEQ ID NO:11.
10. The use of claim 5 or 8, wherein the complex of (b) is to be delivered as a nucleic acid where the IL-15 is co-expressed from separate vectors with a polynucleotide encoding the IL-15Rα-Fc fusion protein.
11. The use of any one of claims 5 to 10, wherein the nucleic acid encoding IL-15 of the complex of (a) and/or the nucleic acid encoding the IL-15 of the complex of (b) encodes a heterologous signal peptide.
12. The use of claim 11, wherein the nucleic acid encoding the IL-15 of the complex of (a) and/or the complex of (b) encodes a native IL-15 in which the native IL-15 signal peptide is replaced with a nucleic acid sequence encoding a signal peptide from a heterologous protein.
13. The use of claim 12, wherein the heterologous protein is tissue plasminogen activator, growth hormone, granulocyte macrophage-colony stimulating factor (GM-CSF) or an immunoglobulin.
14. The use of claim 12, wherein the IL-15 comprises a human GM-CSF/IL-15 fusion of SEQ ID NO:18.
15. The use of any one of claims 1 to 14, wherein the patient is receiving a chemotherapeutic agent.
16. The use of claim 15, wherein the combination is to be administered after a course of treatment with the chemotherapeutic agent.
17. The use of claim 15 or 16, wherein the chemotherapeutic agent is an anti-cancer agent.
18. A use as claimed in any one of claims 1 to 17 substantially as herein described and with reference to any example thereof. 1PC.TXT
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23415209P | 2009-08-14 | 2009-08-14 | |
US23415509P | 2009-08-14 | 2009-08-14 | |
US61/234,152 | 2009-08-14 | ||
US61/234,155 | 2009-08-14 | ||
NZ714757A NZ714757A (en) | 2009-08-14 | 2010-08-13 | Use of il-15 to increase thymic output and to treat lymphopenia |
NZ62500810 | 2010-08-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ736967A NZ736967A (en) | 2020-11-27 |
NZ736967B2 true NZ736967B2 (en) | 2021-03-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11041008B2 (en) | Heterodimers of IL-15 and IL-15R alpha to increase thymic output and to treat lymphopenia | |
EP3645568B1 (en) | Anti-b-cell maturation antigen chimeric antigen receptors with human domains | |
Saudemont et al. | NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells | |
ES2399503T5 (en) | Use of reagents related to mammalian cytokines | |
WO2003087320A2 (en) | Antagonists of il-21 and modulation of il-21-mediated t cell responses | |
WO2020072390A1 (en) | Suicide module compositions and methods | |
US20230374454A1 (en) | Human immune cells genomically modified to express orthogonal receptors | |
WO2017177063A1 (en) | Use of heterodimeric il-15 in adoptive cell transfer | |
Xiong et al. | CAR-NK cell therapy for glioblastoma: what to do next? | |
JP2024515577A (en) | Modified granulocyte colony-stimulating factor (G-CSF) and its binding chimeric cytokine receptor - Patents.com | |
KR20230117341A (en) | Multifunctional and multivalent interleukin-TGF-beta receptor fusion polypeptides | |
Zhang et al. | Low-dose IL-2 therapy in autoimmune diseases: an update review | |
NZ736967B2 (en) | Use of il-15 to increase thymic output and to treat lymphopenia | |
WO2023276395A1 (en) | Chimeric cytokine receptor | |
CN117425679A (en) | Modified granulocyte colony-stimulating factor (G-CSF) and chimeric cytokine receptor binding thereto | |
Hartgring | Role of IL-7 and TSLP in immunopathology of (rheumatoid) arthritis |